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ABSTRACT 
Bioconjugations are utilized in many fields including materials science, 
biochemistry and medicine, despite the limited chemistries available in 
biomolecules. Unnatural amino acids can be used to expand the chemical 
diversity in proteins, affording a greater variety of functional groups for 
bioconjugations which. The site-specific incorporation of unnatural amino acids 
confers greater control and specificity over the reactions. Applications of 
unnatural amino acid based bioconjugations will be explored in this thesis. 
Optimization of solid supported immobilization of GFP and the extension of the 
technology to a carboxylesterase will be described. Fluorescent labeling of a 
medically relevant enzyme, Utag, will be optimized as the first step in 
developing a novel screening system for prostate cancer. Development of 
reactions to functionalize divalent bioconjugates into multivalent complexes will 
also be discussed. The utility of GFP containing an unnatural amino acid will be 
extended using various conjugation partners. Additionally, the unique chemistry 
of 3-fluorotyrosine will be utilized to study the radical pathway of a 
multifunctional hemoglobin, Dehaloperoxidase. In short, unnatural amino acid 
technology will be leveraged to explore novel applications and reactions of 
bioconjugates and the radical pathway of Dehaloperoxidase.  
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Chapter 1: Introduction 
Bioconjugations involve a reaction between a biological macromolecule, 
such as DNA, RNA or protein, and another secondary molecule. The secondary 
molecule can be of biological, organic or inorganic origin, such as a solid 
support, a fluorophore, a radioactive label or another biomolecule.1 
Bioconjugations are ubiquitous tools utilized in biochemistry, materials science, 
and medical applications, for everything from probes to drug delivery 
mechanisms to the development of novel materials.1,3,4 Bioconjugations that 
utilize proteins make use of the few reactive chemical groups present in the 20 
canonical amino acids. However, more useful bioconjugations exist that employ 
chemical functionalities often found outside of a biological context. This is 
primarily due to the orthogonality of these groups affording a higher degree of 
control over the reaction. Two extremely useful bioconjugation reactions are the 
1,3-dipolar cycloaddition (CuAAC) between an alkyne moiety and an azide 
moiety and the Glaser-Hay reaction between two acetylene groups.1 These 
reactions can be applied to proteins via inserting the alkyne or azide moieties 
into proteins via unnatural amino acids (UAAs). These UAAs can be site 
specifically incorporated into proteins using the Shultz methodology, which 
allows for greater control of bioconjugation reactions.  This more sophisticated 
control allows for the development of novel protein-based bioconjugates, some 
of which will be described in this thesis. 
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Examples and Limitations of non-Bioorthogonal Bioconjugations 
Many bioconjugations make use of the relatively limited chemical 
functionality of the 20 natural amino acids. 
The most commonly used functional 
groups used are the amine present in lysine 
residues and the thiol present in cysteines. 
These chemistries are utilized in in ligand-targeted therapeutics (LTTs) to 
covalently attach a therapy molecule to a targeting biomolecule, such as an 
antibody (IgG, Figure 1.1).2 The antibody will only bind to the target cell, where 
it is typically endocytosed, delievering the toxic payload only to diseased cells. 
This prevents the drug from affecting healthy cells, allowing for higher dosage 
of the drug and an increased effectiveness of the therapy.2  
Bioconjugations are also applied in the developing field of protein 
microarrays. These consist of a layer of proteins immobilized on a solid support, 
typically a flat surface. These microarrays have been developed for use in 
clinical applications to replace expensive diagnostic tools in poor countries.3 
Laying down a uniform surface of proteins on these “biochips” is important to 
create reproducible and stable binding of the substrate of interest, but this can 
prove challenging without the use of UAAs. Researchers are forced to use 
either reactive natural amino acids or chemical groups that are added to the 
protein via a chemical reaction with these reactive amino acids.3 Neither of 
Figure 1.1: A LTT bioconjugate.2 
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these methods affords control over the orientation of the protein, resulting in a 
heterogenous layer of the protein.  
Utilizing the naturally 
occurring lysine and cysteine 
allows for facile production of the 
protein of interest, but limits the 
scope of available chemistries for 
bioconjugation. In addition to 
being chemically limited, this 
method of bioconjugation allows 
for a heterogenous mixture of products. For example, when utilizing a reactive 
lysine residue to immobilize an enzyme, there is no way to control which lysine 
residue is reacted with the surface. Some proteins will be conjugated to the 
surface in such a way that the active site will be blocked, rendering that protein 
useless in the reaction (Figure 1.2). This defeats part of the purpose of 
immobilization, by decreasing the effective concentration of active enzyme. 
Additionally, bioconjugation reactions that utilize naturally occurring chemistries 
are not useful for conjugation in biological systems. Since these cysteine and 
lysine residues are common to all proteins, side reactions will occur with other 
proteins besides the protein of interest. UAAs used in conjunction with 
bioorthogonal reactions, such as the CuAAC the Glaser-Hay, offer a solution to 
this cross reactivity. 
Figure 1.2: Two methodologies for enzyme 
immobilization. Utilization of natural reactive groups 
results in a heterogenous layer of randomly oriented 
enzymes, while immobilization using a site specifically 
incorporated UAA results in a homogenous layer of 
protein in a controlled orientation.4 
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Bioorthogonal Bioconjugation Reactions 
The CuAAC reaction employs an azide moiety and an alkyne moiety and 
yields 1,4-linked 1,2,3-triazoles (Scheme 1.1).5 Neither of these chemical 
groups are present in biological systems, making the CuAAC bioorthogonal. 
The CuAAC reaction is an optimization of the Huisgen 1,3-cycloadditon which 
required higher 
temperatures.6 
Meldal and 
Sharpless both 
produced 
improvements 
to this reaction 
in the form of a 
copper catalyst 
that resulted in 
a decrease in 
the 
temperature 
requirements for the reaction.6  The addition of a tetradentate ligand, such as 
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), also improved the 
reaction, as it increased the reaction rate and lower the time needed for the 
reaction.1 The shorter reaction time is advantageous for biological applications, 
Scheme 1.2: Reaction Mechanism for the CuAAC reaction.7 
Scheme 1.1: The CuACC “click” reaction between an acetylene and an azide.5 
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as the catalytic copper can degrade proteins during the reaction.  Copper I is 
thermodynamically prone to oxidation into Cu2+ and disproportionation into Cu0 
and Cu2+.5 This prevents efficient catalysis, as the Cu1+ concentration is 
constantly changing. TBTA solves this problem by binding to the Cu atom. This 
prevents the copper from participating in destabilizing reactions. Additionally, 
the tertiary nitrogen provides greater electron density to the copper center, 
increasing the reaction rates. The 1,2,3-triazole moieties are released from the 
metal to allow for catalytic binding between the copper and the alkyne.5 TCEP 
is a reducing agent that also helps prevent the oxidation of the copper. The 
reaction proceeds through the mechanism illustrated in Scheme 1.2. This click 
reaction can be utilized with proteins containing either the para-
propargyloxyphenylalanine (pPrF) or para-Azidophenylalanine (pAzF) UAAs to 
conjugate proteins to a fluorophore (Chapter 4), a solid support (Chapter 2) or 
other secondary reaction partners.  
The other main bioconjugation reaction utilized in this thesis is the 
Glaser-Hay reaction, which involves the coupling of two terminal alkynes to 
form a diyne (Scheme 1.3).  
This diyne linkage is useful in 
bioconjugation reactions as it 
allows for bioorthogonal 
reactions and provides an electron dense linkage that can be utilized in other 
reactions to create a multivalent complex (Chapter 5). The organic version of 
Scheme 1.3: Overall Reaction of two acetylenes 
through the Glaser-Hay reaction.8 
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this reaction was first described by Glaser as an optimization of the Eglinton 
reaction, using only catalytic copper.9 This reaction was further improved by the 
addition of TMEDA by Hay. The TMEDA functions as a bidentate ligand that 
stabilizes the Cu I, similar to the TBTA function in the CuAAC reaction.9 The 
reaction mechanism was studied computationally using the DFT methodology, 
and the resulting proposed reaction mechanism is shown in Scheme 1.4.10 This 
reaction was not utilized in bioconjugation until it was optimized for biological 
conditions by Lampkowski and co-workers in 2015. Lampkowski et al.  found 
that the reaction proceeds best at 4 ˚C for 6 h. This results in 93% coupling 
between the fluorophore and the protein without undue amounts of protein 
degradation.8 Minimal homodimerization between the fluorophore and the GFP 
was observed, likely due to the bulk of the protein1,8 This reaction can be utilized 
in proteins containing pPrF or pEtF to immobilize the protein (Chapter 2), to 
label the protein with a fluorophore (Chapter 4), or to conjugate the protein with 
Scheme 1.4: Computationally generated reaction mechanism for the Glaser-Hay reaction.10 
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an aromatic partner to change the function of the protein (Chapter 6). These 
UAAs are incorporated into proteins via the Schultz methodology, which 
exploits the central dogma of molecular biology. 
Central Dogma of Molecular Biology 
Incorporation of unnatural amino acids takes advantage of the natural 
protein synthesis mechanisms in Escherichia coli. The two steps of protein 
synthesis are transcription and translation, which are linked together in the 
central dogma of molecular biology (Figure 1.3).11,12 An organism’s DNA stores 
the information needed for the synthesis of a particular protein as a gene, a 
unique sequence made up of four nucleotide bases.12 These nucleotides are 
arranged into different groups of three to form codons, which each code for an 
amino acid.12 During transcription, the DNA encoding the protein is used as a 
template for RNA Polymerase to synthesize mRNA. Once the gene has been 
transcribed, the mRNA is then transported out of the nucleus.12 These mRNAs 
enter the cytoplasm, and a ribosome is assembled around them. The ribosome 
Figure 1.3: The Central Dogma of molecular 
biology.11 
Figure 1.4: Translation of mRNA into a Polypeptide via 
charged tRNAs.13 
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uses tRNAs charged with amino acids to translate the codons in the mRNA 
sequence into a chain of amino acids, known as a polypeptide (Figure 1.4). The 
polypeptide will then fold to create secondary and tertiary structures, resulting 
in the final form of the protein.12   
During translation, the mRNA sequence is converted to amino acids 
using a tRNA charged with a specific amino acid. (Figure 1.4). The tRNA is 
charged with its amino acid by a specific aminoacyl tRNA synthetase (aaRS) in 
a reaction known as aminoacylation (Figure 1.5). The tRNA and corresponding 
aaRS are known as a 
tRNA/aaRs pair. The aaRS 
contains highly selective 
binding sites for the amino 
acid and tRNA, ensuring 
that they are paired together 
correctly.12 Once both the tRNA and the proper amino acid are bound to the 
aaRS, it facilitates the acylation reaction that charges the tRNA with the amino 
acid.12  
Current Methodology for the Site-specific Incorporation of UAAs 
These natural tRNA/aaRS pairs can be engineered to incorporate UAAs 
into proteins via a methodology developed by the Schultz lab for use in E. coli. 
The tRNA/aaRS pairs are developed to participate in amber suppression. 
Amber suppression occurs when the little-used amber stop codon (TAG) is 
Figure 1.5: Charging a tRNA with an amino acid.14 
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employed to replace the codon of a natural amino acid.15 This codon is then 
used to site-specifically insert an unnatural amino acid via specific tRNA/aaRS 
pairs that correspond to the TAG codon.15 An aaRS is selected after a double 
sieve selection (Figure 1.6). Mutant synthetases are evolved by randomly 
mutating four sites, thought to be involved in tyrosine bonding, in a natural 
tyrosine aaRS from Methanococcus jannaschii (Mj).16 A library of mutant aaRS 
is developed by generating primers containing a with a random mutation at one 
of the 4 or 5 sites. This library of primers is then used in a mutagenic PCR with 
template plasmid of natural Mj aaRS.17 This library of mutant synthetase 
plasmids is then transformed into E. coli cells via electroporation. 
Electroporation is used instead of heat shock because it affords the higher 
transformation efficiencies needed to ensure that each plasmid in the library is 
incorporated into a cell. The synthetase library is co-transformed with a plasmid 
Figure 1.6: Positive and negative selection utilized to screen for a highly selective aaRS.17 
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containing a chloramphenicol resistance.17 The gene contains a TAG codon in 
place of a tyrosine, so the cell must be able to read through the TAG to utilize 
the chloramphenicol resistance. This feature is utilized in the positive selection 
that takes place immediately after the transformation. The cells are plated on 
media containing the UAA of interest and chloramphenicol.16,17 Any cells 
containing synthetase mutants who can charge either natural tyrosine or the 
desired UAA to the tRNA survive, and the synthetase plasmids are then put 
through a negative selection. In the negative selection, the mutant synthetase 
plasmid is transformed into new cells along with a plasmid containing a gene 
for barnase, a cytotoxin.17 The barnase gene contains three TAG mutations. 
The cells are grown without the unnatural amino acid, so only the synthetases 
that charge the tRNA with natural tyrosine will read through the TAG mutations 
in the barnase gene.17 These cells will produce barnase and die, leaving only 
the cells containing synthetases that only charge the unnatural. Several rounds 
of both the positive and negative selection occur to ensure that only the 
synthetases that are most selective for the unnatural survive.16,17 To develop 
the tRNA, a tyrosine tRNA from M.  jannaschii is mutated to correspond to the 
amber stop codon and 11 nucleotides that don’t bind to the Mj aaRS were 
randomly mutated, then put through several negative selections using the 
barnase gene to ensure its selectivity for the evolved aaRS.15,17 The resulting 
tRNA/aaRS pair is highly selective and therefore orthogonal to the native 
protein machinery of E. coli, ensuring that the UAA is reliably inserted into the 
protein.  
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To apply this tRNA/aaRS set, two pET plasmids can be transformed into 
electrically competent E. coli cells, one containing the TAG mutant protein 
gene, and the other containing the tRNA/aaRS genes (Figure 1.6).1,15 The 
protein gene is typically 
under an isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
promoter with ampicillin 
(amp) resistance and the 
tRNA/aaRS genes are under 
an arabinose promoter with a 
chloramphenicol (chlor) 
resistance gene.15 When the 
log-phase cells are grown in 
the presence of arabinose, 
IPTG, amp, chlor and the 
desired UAA, the orthogonal 
tRNA/aaRS pair charges the 
tRNA with the UAA of interest 
(Figure 1.7). This charged 
tRNA is then incorporated 
into the protein at a specific site in response to the amber stop codon via the 
M. jannaschii protein machinery.15 As such, mutated protein can be expressed 
in mg/L yields.18 This technology is extremely useful in determining the 
Figure 1.7: Expression of UAA-containing GFP using the 
Schultz methodology.1 
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structure-function relationships in proteins, and in conferring new functions to 
proteins, such as the ability to participate in bioorthogonal bioconjugations. 
Unnatural amino acids have provided a new tool to optimize 
bioconjugation reactions. They allow for greater control of the reaction by 
offering biorthogonality and site specific incorporation, which increases the 
efficiency and utility of many applications of bioconjugates. Additionally, the 
Glaser-Hay reaction that can be accessed using UAAs creates the possibility 
for multivalent bioconjugation reactions, yielding the possibility of advances in 
medical, medicinal and biochemistry fields. Some applications of UAAs to 
bioconjugates are explored in this thesis, including protein immobilization, 
enzyme labeling, multivalent reactions and protein functionalization. UAAs are 
also explored in the context of chemical probes to examine the radical pathway 
of a multifunctional hemoglobin.  
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Chapter 2: Immobilization of GFP to Stabilizing 
Resin 
Proteins are capable of catalyzing a wide range of chemical 
transformations, and their utility transcends the realm of biology, finding 
application in organic synthesis, materials chemistry, and alternative energy 
technologies.1−3 However, a major limitation to exploiting the utility of proteins 
in a more chemical setting is their lack of stability and activity in nonaqueous 
environments.2,4−10 The immobilization of proteins has proven to be an effective 
mechanism to expand their utility into nonbiological contexts. Moreover, 
immobilization confers the ability to recover and reuse relatively expensive 
enzymatic catalysts, and a better means of reaction control as catalysis can be 
halted by a simple filtration to remove the immobilized enzyme.11 Immobilized 
enzymes have a wide range of applications including organic catalysis, 
microarrays, imaging probes, and biosensors.12−17 While many general 
protocols already exist for protein immobilization (encapsulation, adsorption, 
and covalent attachment), there remains room for significant improvement.18,19 
For many uses of proteins, covalent immobilization provides a number of 
advantages including increased thermal stability, better scale up potential, and 
decreased probability of protein desorption, contaminating the reaction 
solution. However, many covalent modification approaches rely upon reactive 
residues (e.g., lysine and cysteine) on protein surfaces for attachment.20 This 
16 
 
can lead to alteration in protein selectivity and activity, and may lead to 
complete inactivation as the active site may be blocked by the solid support.19,21 
Additionally, there is a general lack of control over how many residues react 
with the surface and remaining unreacted functionality on the surface, which 
may impede the catalysis via reaction with substrates and produce undesired 
heterogeneous mixtures on the solid support.11 Many of the above problems 
can be solved by unnatural amino acid (UAA) directed immobilization of the 
protein of interest. 
We set out to address issues associated with nonspecific protein 
immobilization through the use of unnatural amino acids. The site-specific 
incorporation of UAAs represents a novel mechanism to control protein 
immobilization via the introduction of a single residue that displays 
bioorthogonal reactivity. 22,23 The Schultz method for incorporating UAAs is 
advantageous over other mechanisms to incorporate UAAs, as the technology 
abrogates issues associated with protein size, scale, and delivery, as well as 
establishes a permanent, self-sustained system for protein production (not 
requiring the synthesis of precursors for each protein production).24−27 The 
Schultz methodology has been utilized in the reaction of calmodulin onto carbon 
nanotubes and nanoparticles via the Staudinger-Bertozzi ligation,31,32 as well 
as the immobilization of other proteins to M-20 Dynabeads in a cell-free system 
and indirectly via streptavidin derivatized gold surfaces with a click reaction.16,17 
Finally, a similar approach was performed using an agarose resin and azido 
17 
 
UAA to “catch” proteins for secretome MS analysis; however, in this case the 
UAA was not site-specifically incorporated into the pool of proteins.33 The 
combination of these studies demonstrates the utility of site-specific 
immobilization, and the stabilizing benefits of the solid support; however, a 
more extensive investigation of immobilization methods and variables has the 
potential to advance this promising field.  
Results and Discussion 
Moreover, 
development of a 
generalized 
protocol and better 
understanding of 
immobilization 
conditions is 
needed to adapt 
unnatural amino 
acid technologies to 
protein 
immobilizations, 
and fully exploit this 
powerful system. 
Specifically, the p-
Figure 2.1: Protein and resin preparation. (A) p-Azidophenylalanine (pAzF) 
unnatural amino acid possessing an azide functionality for click conjugations. 
(B) Series of alkynols used for resin derivitization, varied methylene units 
confer differential flexibility for protein attachment. (C) SDS-PAGE analysis 
of pAzF-GFP-151 expression. No protein is present in the absence of the 
UAA (lane 1) suggesting successful incorporation of the UAA (lane 2). 
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azidophenylalanine (pAzF) UAA was selected due to its ability to participate in 
bioorthogonal 1,3-dipolar cylcoaddition “click” reactions with an alkyne (Figure 
2.1A). This reaction has found wide use in biological chemistry due to its unique 
reactivity (relative to the natural 20 amino acids), water compatibility, and 
overall efficiency.34,35 Fortuitously, an aaRS has already been evolved to 
facilitate the incorporation of this UAA.36,37 In order to rapidly and easily assess 
the protein 
immobilization, green 
fluorescent protein (GFP) 
was selected as a model 
protein, and expressed 
with pAzF at surface 
exposed residue 151 
using a pET-GFPY151TAG plasmid (Figure 2.1C). The mutated GFP 
containing the UAA retained its fluorescence relative to wild-type protein, and 
served as a functional reporter for the immobilization. Furthermore, as the 
fluorescence of GFP is not dependent on the orientation of immobilization 
(Figure 2.2), GFP was able to serve as a good model protein for the quick 
assessment of immobilization efficiency when different orientations were 
considered. It is important to note that this orientational independence does not 
necessarily translate to enzymes, and additional considerations must be made 
when adapting the approach.  
Figure 2.2: Fluorescence spectra of pAzF-GFP mutants and wild 
type protein (Ex. 395 nm). 
19 
 
Initially, attempts were made to ascertain the best material for the solid 
support. A range of supports was assessed including polystyrene, Tenta-Gel, 
and Sepharose resins. The solid support was evaluated based on 
immobilization efficiency, and retention of GFP fluorescence. As a proof-of 
concept, a representative of each class of support was examined. A 
tritylchloride modified polystyrene resin, an epoxide derivatized Sepharose 6B, 
and a carboxy-modifed Tenta-Gel resin were all derivatized with an alkynyl 
linker to facilitate click chemistry with the azide on the protein surface. 
Conveniently, each resin is reactive with alcohol functionalities under 
appropriate conditions, and each was subjected to immobilization with 
propargyl alcohol, 1-hexynol, or 1-undecynol to vary the length of the carbon 
tether separating the reactive alkyne from the solid-support (Figure 2.1B). 
These linkers were selected due to their low cost and commercial availability. 
Moreover, the linkers provided a mechanism for the assessment of linker length 
and immobilization efficiency. Alkyne immobilization and approximate resin 
loading was determined by cleavage of 15 mg of resin followed by GC/MS and 
TLC analysis, affording loadings of 0.6−0.9 mmol/g of immobilized alkyne. 
Resin loadings at these concentrations should ideally be low enough to 
adequately provide enough spatial protein separation to retain function; 
however, lower loadings may be necessary if protein function is inhibited. 
Additionally, the immobilization capability of propargyl amine instead of an 
alkyn-ol was tested by immobilizing propargyl amine to the sepharose resin and 
subsequently reacting the loaded resin with pAzf-GFP- 151. Similarly, the ability 
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of an azide- derivatized sepharose to immobilize p-propargyloxyphenyalanine 
(pPrF)-GFP-151 was tested. Both variations of loading the sepharose resin 
resulted in GFP immobilization, but were never compared to the propargyl 
alcohol loading method. 
After confirmation of immobilization the different resins were subjected 
to click conditions for 16 h at 4 °C. The amount of resin utilized was normalized 
to the corresponding loading in order to ensure 12 μmol of immobilized alkyne 
reacted with a normalized 35 μg of GFP protein. In order to prevent aggregation 
of both the polystyrene and Tenta-Gel resins 10% DMSO was added. To verify 
that DMSO did not affect protein stability fluorescence spectra were taken in 
both the presence and absence of 10% DMSO (Figure 2.3). Resins were then 
transferred to 
spin columns and 
washed 5 times 
with PBS buffer. 
The presence of 
GFP was 
assessed both 
visually on a 
transilluminator and with a fluorescence plate reader (Ex. 482/Em. 520). While 
little to no fluorescence was observed on the polystyrene resin, definitive 
immobilization was noted on both the Tenta-Gel and sepharose resins, with the 
Figure 2.3: Fluorescence spectrum of pAzF-GFP-151 in the prescence and 
absence of 10% DMSO. 
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fluorescence intensity being much greater on the sepharose resin. The 
decreased immobilization efficiency is most likely due to polystyrene resin 
aggregation in aqueous solvents. The immobilization of the GFP on the 
polystyrene and Tenta-Gel resins may be further improved via optimization of 
organic solvent ratios to accommodate the resin while not denaturing the 
protein of interest. However, these results do demonstrate that the GFP is 
capable of being 
immobilized on a solid 
support without 
affecting protein 
function, as 
fluorescence is 
maintained.  
While all resins 
with all three alkynes 
were analyzed, the 
resin immobilized with 
propargyl alcohol 
reproducibly yielded 
the highest levels of 
GFP fluorescence with 
the sepharose resins 
Figure 2.4: Resin and linker optimization. (A) Fluorescence data from 
alkyne derivatized Sepharose 6B resins conjugated with the pAzF GFP-
151 mutant. Methylene units were varied with the alkyne substrate, and 
maximal fluorescence was observed with propargyl alcohol. A control 
resin using WT GFP (no azide functionality) demonstrated very little 
background fluorescence. All error bars represent standard deviations 
from three independent experiments. (B) Visualization of resin 
immobilization, as no fluorescence is observed under identical 
immobilization conditions using WT-GFP. Resin reacted with the pAzF-
GFP-151 is notably fluorescent. 
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(Figure 2.4). Gratifyingly, resin incubated with wild-type GFP (containing no 
azide functionality) displayed little to no fluorescence, and conditions involving 
pAzF-GFP-151 in the absence of copper catalyst had similar results. This 
confirms that the click reaction was the site of immobilization and noncovalent 
interactions were not responsible for the immobilization event. Also, the 
absence of fluorescence indicates that the sepharose resin is not prone to 
noncovalent “stickiness” and thus only the desired protein can be immobilized. 
This confirms that the protein is only immobilized via the UAA in a controlled 
orientation, not in a random orientation via nonspecific interactions. 
Additionally, the effect of linker length could also be examined in the initial 
experiments. A trend was observed as decreased immobilization efficiency was 
correlated to increased methylene units, with undecynol affording the lowest 
GFP immobilization (Figure 2.4A). Similar results were observed even with 
increased immobilization times. It is possible that the increased flexibility of the 
linker leads to more conformational freedom that inhibits the proper orientation 
for the conjugation of the polymeric resin with the biopolymer.  
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With optimized immobilization conditions in hand, the propargyl alcohol 
derivatized sepharose resin was utilized to ascertain if UAA context is important 
for protein immobilization. A TAG mutation was introduced into the pET-GFP 
plasmid at residues 3,133, and 151, and the corresponding GFP mutants were 
expressed containing the pAzF UAA 
and diluted to identical 
concentrations (Figures 2.2 and 2.5). 
These residues were selected due to 
their differing protein context and 
variable rotational flexibility, while 
maintaining solvent exposure. To 
ensure that changes in fluorescence 
were due to immobilization and not 
altered spectra, the fluorescence 
spectra of all mutants were taken 
(Figure 2.2). The mutants were 
subjected to click conditions for 16 
h at 4 °C as previously described. Visualization of the immobilization indicated 
that selection of UAA residue is important in the immobilization strategy (Figure 
2.6). These results were confirmed by analysis of resin fluorescence on a plate 
reader.  
Figure 2.5: SDS-PAGE analysis of expressed and 
purified GFP mutants containing pAzF at the indicated 
residue. 
Figure 2.6: GFP immobilization on propargyl alcohol 
derivatized Sepharose 6B resin with various pAzF-
GFP mutants. No detectable immobilization occurred 
under control conditions using a WT GFP protein 
without the azide functionality. 
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Residues 3 and 133 are contained within loop motifs at opposite ends of 
the β-barrel, while residue 151 is at the terminus of a β-sheet member of the β-
barrel (Figure 2.7A). Due to the differential degree of immobilization despite 
identical conditions and GFP concentrations, there does seem to be a context 
effect for the placement of the UAA (Figure 2.7B). The highest degree of 
immobilization was observed at residue 151, followed by residues 133 and 3, 
respectively. These trends mimic those observed when selecting optimal linker 
flexibility with the most rigid residue possessing the highest immobilization 
efficiency. Residue 3 is at the 
N-terminus of the protein and 
in a very unstructured region, 
possessing a significant 
degree of conformational 
freedom. Conversely, residue 
151 is extremely structured 
and very little rotational 
freedom can be achieved. This 
rigidity may be useful in 
facilitating the click reaction to 
the resin by holding the azide 
in the proper orientation. 
Residue 133 has intermediate 
conformational flexibility, as 
Figure 2.7: UAA residue context dependence on 
immobilization. (A) Various GFP pAzF mutants were 
expressed with the UAA at different positions (highlighted in 
blue), adapted from PDB: 1EMA.39 (B) Fluorescence data 
demonstrating maximal immobilization with the pAzF-GFP-
151 mutant, suggesting some importance of UAA context 
within the protein for the immobilization. All error bars 
represent standard deviations from three independent 
experiments. 
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well as intermediate immobilization yield. Again, little to no fluorescence was 
observed when the 
copper catalyst was 
removed from the 
reaction as a control. 
These results indicate 
that when utilizing UAA 
bioorthogonal handles 
for protein 
immobilization, some 
consideration must be 
given to the site of UAA 
incorporation to 
maximize 
immobilization 
efficiency as well as 
retain protein function.  
Figure 2.8: Resin stabilization of GFP in organic solutions. (A) 
Incubation of both immobilized GFP and GFP in solution with 
increasing DMF concentration demonstrates a decrease in 
fluorescence for only the solution phase GFP in increased organic 
solvent. (B) Incubation of both resin-bound GFP and solution phase 
GFP with different organic solvents leads to a marked difference in 
fluorescence values. All error bars represent standard deviations from 
three independent experiments. 
26 
 
In order to demonstrate the utility of resin immobilization, the retention 
of GFP fluorescence was examined when exposed to different organic solvents. 
Due to its miscibility, we first exposed the resin and free GFP-151 mutant to 
varied percentages of DMF (25−100%), and incubated the proteins for 2 h, the 
fluorescence was then measured on a plate reader as an indicator of functional 
protein. In agreement with literature precedence, GFP fluorescence decreases 
dramatically in solutions above 50% DMF; however, immobilized GFP 
fluorescence was retained, even at 100% DMF (Figure 2.8A).38 Moreover, 
when incubated in other 
pure organic solvents 
including 
dichloromethane, ethyl 
acetate, and hexanes, a 
significant differential in 
fluorescence was 
observed and quantified on a BioRad gel imaging system (Figures 2.8B and 
2.9). It should be noted that these observed increases in stability are not limited 
to the site-specifically immobilized GFP; however, the success of this method 
does demonstrate its potential usefulness with regard to proteins that are more 
sensitive to the orientation of immobilization. In addition, while some basic 
solvation sphere around the protein may exist, the protein remained stable on 
the resin even when subjected to 48 h incubation times and sonication, while 
solution based protein readily denatured. In summary, this increased protein 
Figure 2.9: Non-aqueous solvent studies of immobilized GFP. Top 
set of tubes contained GFP immobilized on Sepharose 6B resin, 
resulting in retention of some fluorescence/protein function in all 
solvents. Bottom set of tubes contain solution phase GFP in the 
same solvents, demonstrating a loss of function in the non-
aqueous media. 
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stability suggests this methodology can prove useful in the immobilization of a 
variety of proteins for use in nonaqueous catalysis, and coupled with the 
specificity of the immobilization technique, could afford heightened enzymatic 
efficiencies to current technologies. 
These results will be extended to a more industrially relevant protein and 
the immobilization procedure will be further optimized using microwave 
technology. The enzyme used for these studies is a hyperthermophilic 
carboxylesterase of Sulfolobus solfataricus, a thermoacidophile found in 
volcanic muds.40 This protein is abbreviated SSO. SSO provides a spatially 
constrained binding pocket and easily quantifiable chemical enzymatic activity. 
The position of the UAA will be optimized to yield maximum enzymatic function 
and stability in non-aqueous solvents. The high temperature tolerance of SSO 
carboxylesterase will also allow for experimentation with high temperature 
immobilization conditions that could shorten the immobilization reaction time. 
SSO is a more industrially relevant enzyme than GFP that will be used to 
optimize immobilization conditions for proteins that perform chemical 
transformations. 
In conclusion, the utilization of unnatural amino acids has proven to be 
an effective mechanism for the immobilization of proteins. This has far-reaching 
implications toward the extension of protein function to nonbiological 
conditions. Moreover, this methodology is advantageous when compared to 
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existing techniques due to the high level of immobilization control, and its ability 
to generate covalently linked proteins in a homogeneous fashion.  
Materials and Methods 
Solvents and reagents were obtained from either Sigma-Aldrich or Fisher 
Scientific and used without further purification, unless noted. Tritylchloride 
resin, 100200 mesh, 1% DVB crosslinking, and Tenta-Gel-COOH (130 µm 
beads) were purchased from Chem-Impex International. Epoxy-activated 
Sepharose 6B was obtained from GE Healthcare. Reactions were conducted 
under ambient atmosphere with solvents directly from the manufacturer. All 
GFP proteins were purified according to manufacturer’s protocols using a 
Qiagen Ni-NTA Quik Spin Kit. 
Immobilization of Alkynes onto Trityl Chloride Resin: To flame dried vial, 
trityl chloride resin (200 mg, 0.36 mmol, 1 equiv.) and dichloromethane (5 mL) 
were added. The resin was swelled at room temperature with gentle stirring for 
15 min. Alkyn-ol (1.2 equiv.) was added to reaction, followed by triethylamine 
(0.2 equiv) for the propargyl alcohol reaction or 4 equiv of pyridine for hexyn-ol 
and undecyn-ol. The mixture was stirred at room temperature for 16 h. The 
resin was transferred to a syringe filter and washed with DCM and MeOH (5 
alternating rinses with 5 mL each). The resin was swelled in CH2Cl2 and dried 
under vacuum for 45 min before further use. Resin (15 mg) was added to an 
Eppendorf tube followed by trifluoroacetic acid (2%, 200 µL). The mixture was 
shaken at room temperature for 1 h, then subjected to thin layer 
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chromatography in 1:1 Hexanes: Ethyl Acetate, GC/MS, and mass difference 
analysis to confirm resin loading. 
Immobilization of Alkynes onto Tenta-Gel Carboxy Resin: To a vial, Tenta-
gel carboxy resin (200 mg, 0.046 mmol, 1 equiv.) and dichloromethane (3 mL) 
were added. The resin was swelled at 30 ̊ C for 15 minutes. Alkyn-ol (5 equiv.) 
was added to the swelled resin, followed by 4dimethylaminopyridine (DMAP, 
0.2 equiv.) and 1-Ethyl-3-(3-dimethylaminopropyl)3-ethylcarbodiimide 
hydrochloride (ECDI, 5 equiv.). The reaction was stirred at room temperature 
for 16 h. The resin was transferred to a syringe filter and washed with 
dichloromethane and methanol (5 alternating washes with 3 mL each). The 
resin was swelled in DCM and dried under a vacuum for 45 minutes before 
further use. A tetrahydrofuran/methanol solution (4:1, 200 µL) was added to an 
Eppendorf tube along with potassium carbonate (25 mg) followed by resin (15 
mg). The mixture was shaken for 16 h at 37  ̊C. The product was then subjected 
to thin layer chromatography, GC/MS, and mass difference analysis to confirm 
resin loading. 
Immobilization of Alkynes onto Epoxy Sepharose: 6B Resin Epoxy-
activated 6B Sepharose (GE Healthcare, 200 mg) was added to a filter syringe 
and washed with distilled water (5 washes, 3 mL). Alkyn-ol (700 µmol) and 
coupling buffer (3.5 mL, PBS at pH 13.0) was added to a 15 mL tube followed 
by the resin. The mixture was shaken at room temperature for 16 h. The resin 
was transferred to a filter syringe and washed with coupling buffer (4mL). The 
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sepharose was transferred to a 15 mL tube and capped with ethanolamine (3.5 
mL). The resin was incubated at 30 C̊ for four hours then washed in a filter 
syringe with acetate buffer (10 mM) and tris-HCl buffer (pH 4 and pH 8 
respectively, 3 alternating washes with 3 mL each). The same procedure was 
followed to immobilize propargyl amine and 3-azido-1-propargyl amine, except 
the coupling buffer consisted of PBS at pH 10. Additionally, 20 µL of 3-azido-1-
propargyl amine was used instead of 700 µmol of alkyn-amine.  
General GFP Expression: A pET-GFP-TAG variant plasmid (0.5 µL) was co-
transformed with a pEVOL-pAzF plasmid (0.5 µL) into Escherichia coli 
BL21(DE3) cells using an Eppendorf eporator electorporator. The cells were 
then plated and grown on LB agar in the presence of chloramphenicol (34 
mg/mL) and ampicillin (50 mg/mL) at 37  ̊C overnight. One colony was then 
used to inoculate LB media (4 mL) containing both ampicillin and 
chloramphenicol. The culture was incubated at 37  ̊C overnight and used to 
inoculate an expression culture (10 mL LB media, 50 mg/mL Amp, 34 mg/mL 
Chlor) at an OD600 0.1. The cultures were incubated at 37 ̊ C to an OD600 
between 0.6 and 0.8 at 600 nm, and protein expression was induced by addition 
of pAzF (100 L, 100 mM) and 20 % arabinose (10 L) and 0.8 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG; 10 L). The cultures were allowed to shake at 
30 ̊ C for 16-20 h then centrifuged at 5,000 rpm for 10 minutes and stored at -
80 ̊ C for 3 hours. The cell pellet was re-suspended using 500 µL of Bugbuster 
(Novagen) containing lysozyme, and incubated at 37  ̊C for 20 minutes. The 
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solution was transferred to an Eppendorf tube and centrifuged at 15,000 rpm 
for 10 minutes, then the supernatant was poured into an equilibrated His- pur 
Ni-NTA spin (Qiagen) column with of nickel resin (200 µL) and GFP was purified 
according to manufacturer’s protocol. Purified GFP was analyzed by SDS-
PAGE (BioRad 10% precast gels, 150V, 1.5h), and employed without further 
purification. Protein concentrations were determined both by a BCA assay and 
fluorescence measurements. The same protocol was used to express pPrF-
GFP-151, with the substitution of a promiscuous pEVOL-Ambryx plasmid for 
the pEVOL-pAzF plasmid and the pPrF unnatural amino acid for the 
pAzfFunnatural amino acid. 
General GFP Immobilization Conditions: Tris[(1-benzyl-1H-1,2,3-triazol-
4yl)methyl]amine (5 mM, TBTA; 5 µL) was added to an Eppendorf tube along 
containing 4 mM tris(2-carboxyethyl)phosphine (TCEP; 5 µL) and 1 mM CuSO4 
(6 µL). The catalyst system was diluted in phosphate buffered saline solution 
(PBS; 15 µL buffer) and 2.3 mg/mL of GFP-pAzF mutant (15 µL) was added, 
followed by 20 mg of derivatized Sepharose 6B resin (GE Healthcare). This 
mixture was incubated at 4 ̊ C for 16 h then transferred to an empty spin column 
and washed with 1X PBS Buffer (5 x 200 µL) and centrifuged at 3,700 rpm for 
60 s. The reactions were then imaged using a Bio-Rad gel imager (BioRad 
Molecular Imager Gel Doc XR+) and the fluorescence was taken by transferring 
resin to a 96-well plate and measuring relative fluorescence on a plate reader 
(Biotek Synergy HT Microplate Reader). 
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Non-Aqueous Solvent Studies: Dimethylformamide (DMF) solutions were 
prepared via dilution with PBS buffer, yielding 0%, 25%, 50%, 75%, and 100% 
solutions. To an eppendorf tube either 10 µL of pAzF-GFP 151 (2.3 mg/mL) or 
pAzF-GFP-151-Sepharose 6B resin was added followed by the appropriate 
DMF solution in triplicate. The tubes were mixed and incubated at room 
temperature for 2 h then transferred to a 96-well plate and recorded for 
fluorescence (Ex. 482/Em. 520). Fluorescence values were normalized to the 
solution phase or resin condition containing no DMF. Due to solvent 
incompatibility, incubations with dicholormethane, hexanes, and ethyl acetate 
were conducted with pure solvent under similar conditions; however, 
fluorescence was measured by densiometry using a BioRad gel imaging 
system.  
References  
1. Schmid, A., Dordick, J., Hauer, B., Kiener, A., Wubbolts, M., and Witholt, B. 
(2001) Industrial biocatalysis today and tomorrow. Nature 409, 258−268. 
 2. Comfort, D., Chhabra, S., Conners, S., Chou, C., Epting, K., Johnson, M., 
Jones, K., Sehgal, A., and Kelly, R. (2004) Strategic biocatalysis with 
hyperthermophilic enzymes. Green Chem. 6, 459− 465.  
3. Montiel, C., Quintero, R., and Aburto, J. (2009) Petroleum biotechnology: 
Technology trends for the future. Afr. J. Biotechnol. 8, 7228−7240.  
33 
 
4. Sellek, G., and Chaudhuri, J. (1999) Biocatalysis in organic media using 
enzymes from extremophiles. Enzyme Microb. Technol. 25, 471− 482.  
5. Cowan, D. (1997) Thermophilic proteins: Stability and function in aqueous 
and organic solvents. Comp. Biochem. Physiol. 118, 429− 438.  
6. Ayala, M., Verdin, J., and Vazquez-Duhalt, R. (2007) The prospects for 
peroxidase-based biorefining of petroleum fuels. Biocatal. Biotransform. 25, 
114−129.  
7. Lee, M. Y., and Dordick, J. S. (2002) Enzyme activation for nonaqueous 
media. Curr. Opin. Biotechnol. 13, 376−84.  
8. Cruz, J. C., Würges, K., Kramer, M., Pfromm, P. H., Rezac, M. E., and 
Czermak, P. (2011) Immobilization of enzymes on fumed silica nanoparticles 
for applications in nonaqueous media. Methods Mol. Biol. 743, 147−60. 
9. Zaks, A., and Klibanov, A. M. (1988) Enzymatic catalysis in nonaqueous 
solvents. J. Biol. Chem. 263, 3194−201.  
10. Krishna, S. H. (2002) Developments and trends in enzyme catalysis in 
nonconventional media. Biotechnol. Adv. 20, 239−67.  
11. Brady, D., and Jordaan, J. (2009) Advances in enzyme immobilisation. 
Biotechnol. Lett. 31, 1639−1650.  
34 
 
12. Steen Redeker, E., Ta, D. T., Cortens, D., Billen, B., Guedens, W., and 
Adriaensens, P. (2013) Protein engineering for directed immobilization. 
Bioconjugate Chem. 24, 1761−77. 
13. Jiang, X., Li, D., Xu, X., Ying, Y., Li, Y., Ye, Z., and Wang, J. (2008) 
Immunosensors for detection of pesticide residues. Biosens. Bioelectron. 23, 
1577−87.  
14. Vo-Dinh, T., and Cullum, B. (2000) Biosensors and biochips: advances in 
biological and medical diagnostics. Fresenius J. Anal. Chem. 366, 540−51.  
15. Hernandez, K., and Fernandez-Lafuente, R. (2011) Control of protein 
immobilization: coupling immobilization and site-directed mutagenesis to 
improve biocatalyst or biosensor performance. Enzyme Microb. Technol. 48, 
107−22.  
16. Smith, M. T., Wu, J. C., Varner, C. T., and Bundy, B. C. (2013) Enhanced 
protein stability through minimally invasive, direct, covalent, and site-specific 
immobilization. Biotechnol. Prog. 29, 247−54.  
17. Seo, M. H., Han, J., Jin, Z., Lee, D. W., Park, H. S., and Kim, H. S. (2011) 
Controlled and oriented immobilization of protein by sitespecific incorporation 
of unnatural amino acid. Anal. Chem. 83, 2841− 5.  
18. Elgren, T., Zadvorny, O., Brecht, E., Douglas, T., Zorin, N., Maroney, M., 
and Peters, J. (2005) Immobilization of active hydrogenases by encapsulation 
in polymeric porous gels. Nano Lett. 5, 2085−2087.  
35 
 
19. Mateo, C., Palomo, J., Fernandez-Lorente, G., Guisan, J., and Fernandez-
Lafuente, R. (2007) Improvement of enzyme activity, stability and selectivity via 
immobilization techniques. Enzyme Microb. Technol. 40, 1451−1463.  
20. Wilchek, M., and Miron, T. (2003) Oriented versus random protein 
immobilization. J. Biochem. Biophys. Methods 55, 67−70.  
21. Ulbrich, R., Schellenberger, A., and Damerau, W. (1986) Studies on the 
thermal inactivation of immobilized enzymes. Biotechnol. Bioeng. 28, 511−522.  
22. Xie, J., and Schultz, P. G. (2006) A chemical toolkit for proteins–an 
expanded genetic code. Nat. Rev. Mol. Cell Biol. 7, 775− 82.  
23. Wang, L., and Schultz, P. G. (2004) Expanding the genetic code. Angew. 
Chem., Int. Ed. Engl. 44, 34−66.  
24. Yee, C. S., Seyedsayamdost, M. R., Chang, M. C. Y., Nocera, D. G., and 
Stubbe, J. (2003) Generation of the R2 subunit of ribonucleotide reductase by 
intein chemistry: insertion of 3-nitrotyrosine at residue 356 as a probe of the 
radical initiation process. Biochemistry 42, 14541−14552.  
25. Seyedsayamdost, M. R., and Stubbe, J. (2006) Site-specific replacement 
of Y356 with 3,4-dihydroxyphenylalanine in the β2 subunit of E. coli 
ribonucleotide reductase. J. Am. Chem. Soc. 128, 2522−2523.  
26. Seyedsayamdost, M. R., Yee, C. S., and Stubbe, J. (2007) Sitespecific 
incorporation of fluorotyrosines into the R2 subunit of E. coli ribonucleotide 
reductase by expressed protein ligation. Nat. Protoc. 2, 1225−1235.  
36 
 
27. Duffy, N., and Dougherty, D. (2010) Preparation of translationally competent 
tRNA by direct chemical acylation. Org. Lett. 12, 3776−3779.  
28. Young, T. S., and Schultz, P. G. (2010) Beyond the canonical 20 amino 
acids: expanding the genetic lexicon. J. Biol. Chem. 285, 11039− 11044.  
29. Liu, C. C., Mack, A. V., Tsao, M. L., Mills, J. H., Lee, H. S., Choe, H., Farzan, 
M., Schultz, P. G., and Smider, V. V. (2008) Protein evolution with an expanded 
genetic code. Proc. Natl. Acad. Sci. U. S. A. 105, 17688−93.  
30. Link, A. J., Mock, M. L., and Tirrell, D. A. (2003) Non-canonical amino acids 
in protein engineering. Curr. Opin. Biotechnol. 14, 603− 609.  
31. Yoshimura, S. H., Khan, S., Ohno, S., Yokogawa, T., Nishikawa, K., 
Hosoya, T., Maruyama, H., Nakayama, Y., and Takeyasu, K. (2012) Site-
specific attachment of a protein to a carbon nanotube end without loss of protein 
function. Bioconjugate Chem. 23, 1488−93.  
32. Ikeda-Boku, A., Kondo, K., Ohno, S., Yoshida, E., Yokogawa, T., Hayashi, 
N., and Nishikawa, K. (2013) Protein fishing using magnetic nanobeads 
containing calmodulin site-specifically immobilized via an azido group. J. 
Biochem. 154, 159−65. 
33. Eichelbaum, K., Winter, M., Diaz, M., Herzig, S., and Krijgsveld, J. (2012) 
Selective enrichment of newly synthesized proteins for quantitative secretome 
analysis. Nat. Biotechnol. 30, 984.  
37 
 
34. Best, M. D. (2009) Click chemistry and bioorthogonal reactions: 
unprecedented selectivity in the labeling of biological molecules. Biochemistry 
48, 6571−84.  
35. Jewett, J. C., and Bertozzi, C. R. (2010) Cu-free click cycloaddition 
reactions in chemical biology. Chem. Soc. Rev. 39, 1272−9.  
36. Deiters, A., Cropp, T. A., Summerer, D., Mukherji, M., and Schultz, P. G. 
(2004) Site-specific PEGylation of proteins containing unnatural amino acids. 
Bioorg. Med. Chem. Lett. 14, 5743−5.  
37. Chin, J. W., Santoro, S. W., Martin, A. B., King, D. S., Wang, L., and Schultz, 
P. G. (2002) Addition of p-azido-L-phenylalanine to the genetic code of 
Escherichia coli. J. Am. Chem. Soc. 124, 9026−7.  
38. Raghunathan, G., Sokalingam, S., Soundrarajan, N., Munussami, G., 
Madan, B., and Lee, S. (2013) A comparative study on the stability and 
structure of two different green fluorescent proteins in organic cosolvent 
systems. Biotechnol. Bioprocess Eng. 18, 342−349.  
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Chapter 3: Initial Steps Towards 
Carboxylesterase Immobilization 
Enzymes are widely used in industrial applications to catalyze complex 
reactions in a highly efficient fashion, allowing manufacturers to streamline 
synthetic protocols. While enzymes can facilitate efficient syntheses, they also 
pose a unique set of challenges.1,2 Enzymes are expensive and fragile 
reagents, requiring a specific pH, salt concentration and temperature to remain 
functional. They are also incompatible with organic solvents and detergents as 
these chemicals cause denaturation, which results in a loss of functionality. 
Enzyme immobilization offers a solution to these challenges, as it stabilizes 
proteins under denaturing conditions.3-5 Additionally, immobilization offers the 
possibility of recovering expensive enzymes via simple filtration, which is both 
cost-efficient and environmentally friendly.  
There are many established methodologies for immobilizing enzymes, 
including adsorption and covalent reaction with reactive natural amino acids.3 
The main weakness of these methods is that they afford no control over the 
orientation of the protein relative to the solid support. This can result in a 
heterogeneous layer of proteins on the solid support, where the active sites of 
some of the proteins are blocked from the solvent by the solid support (Figure 
3.1).6-8 This steric hindrance can prevent proteins from binding their substrate 
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and performing their enzymatic 
function, decreasing the overall 
catalytic capacity of the enzyme 
preparation. Unnatural amino 
acids (UAAs) can be used to solve 
this problem by offering precise 
control over the orientation of the 
protein relative to the solid 
support, as well as provide a homogenous immobilization. A surface exposed 
UAA can be site-specifically inserted into an enzyme with minimal to no impact 
on catalytic function. This UAA then provides a chemical handle that can be 
employed in bioorthogonal reactions to immobilize the enzyme onto a solid 
support in an orientation-controlled manner. 
This immobilization method has been optimized in the previous chapter 
using GFP. In that research, we proved that it is feasible to utilize UAAs to 
immobilize a protein without interfering with its function. However, GFP is not 
an “enzyme,” and thus we aim to expand the 
scope of this methodology to more interesting 
proteins. SSO Carboxylesterase P1 (SSO Est) 
was selected to serve as a model protein to 
extend the technology to an enzyme with 
measurable catalytic function. SSO Est is a hyperthermophilic enzyme that 
Figure 3.1: Two methodologies for enzyme 
immobilization. Utilization of natural reactive groups 
results in a heterogenous layer of randomly oriented 
enzymes, while immobilization using a site specifically 
incorporated UAA results in a homogenous layer of 
protein in a controlled orientation.6 
Figure 3.2: Immobilization of SSO 
Carboxylesterase P1 via a diyne 
linkage from the Glaser-Hay 
reaction. 
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cleaves an ester into an alcohol and an aldehyde.9,10 This protein will provide a 
platform from which to extend the UAA-mediated immobilization technique to 
industrially relevant mesophilic and hyperthermophilic enzymes, as well as to 
optimize activation conditions for hyperthermophilic enzymes (Figure 3.2).   
This enzyme affords several advantages over GFP and mesophilic 
enzymes for this stage of the immobilization optimization. Unlike GFP, SSO Est 
catalyzes an organic reaction, so the kinetics of the immobilized and wild type 
enzyme can be compared. This will allow for further optimization of the 
immobilization strategy to prevent perturbation of the catalytic function of the 
enzyme. Additionally, SSO Est is unusually stable and performs optimally at 
high temperatures.9 This stability of this enzyme will make it easier to optimize 
immobilization and catalytic conditions as the enzyme is likely to maintain its 
activity in situations where more fragile mesophilic enzymes might not, such as 
microwave-assisted applications and reactions in organic solvents. These 
reaction conditions can then be extended to mesophilic proteins or other 
industrially useful hyperthermophilic proteins to yield solid supports with the 
maximum amount of loaded and active protein.  
The added stability afforded by immobilization to SSO Est will also allow 
for optimization of activation conditions. Hyperthermophilic enzymes exhibit a 
low degree of conformational flexibility at normal physiological temperatures, 
which prevents destabilization of the non-covalent interactions holding the 
enzyme in its tightly folded state.9 This rigidity also prevents hyperthermophilic 
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enzymes from performing their intended enzymatic activity at relatively low 
temperatures. To activate these enzymes for catalysis, the conformational 
flexibility must be increased. This is usually accomplished by increasing the 
temperature, but can also be accomplished by the addition of small amounts of 
denaturants or co-solvents to the solution at lower temperatures.9 Microwave 
irradiation can also be used to activate hyperthermophilic enzymes at 
temperatures below their optimum temperature. The microwaves are thought 
to cause a rapid dipole alignment of the peptide bonds, which generates 
molecular motion.11 This increase in molecular motion mimics the effect of high 
temperatures, causing the protein to become more flexible. Unfortunately, 
chemical or microwave activation can lead to denaturation of the enzymes.11 
UAA mediated immobilization will offer further stability to hyperthermophilic 
enzymes, preventing denaturation and expanding the range of activation 
conditions that can be utilized.  
SSO Est will be used to further optimize a UAA mediated immobilization 
methodology that has been proven to stabilize GFP under denaturing 
conditions. Once the immobilization strategy is optimized for SSO Est, the 
methodology can be extended to other hyperthermophilic proteins as well as 
more sensitive mesophilic proteins that are utilized in industrial reactions. 
Immobilized SSO Est will also be used to optimize activation conditions for 
hyperthermophilic enzymes, which can them be extended to other 
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hyperthermophilic enzymes to maximize their catalytic efficiency at lower 
temperatures. 
Results and Discussion 
The wild type (WT) SSO Est plasmid was obtained from the laboratory 
of Robert Kelly at North Carolina State University. Three surface exposed 
tyrosine residues were selected for mutation based on the crystal structure. 
SSO Est Y90TAG (SSO 90), SSO Est Y116TAG (SSO 116) and SSO Est 
Y191TAG (SSO 191) mutants were prepared using Quik-Change PCR site 
directed mutagenesis. SSO 90 and SSO 191 reactions exhibited the most 
differential growth, compared to a negative control, under conditions using 
template plasmid concentrations of 24.7 ng/μL and 12.3 ng/μL. SSO 116 
exhibited the most differential growth under conditions using template plasmid 
concentrations of 24.7 ng/μL and 6.2 ng/μL.  Successful insertion of the TAG 
mutation was confirmed by sequencing at Genewiz using primers designed for 
the T5 promoter present in the pQE-30 backbone of the SSO Est plasmid. The 
insertion of the TAG mutation was successful in all the reactions containing 
24.7 ng/μL of template plasmid, as well as in the SSO 116 reaction containing 
6.2 ng/μL of template plasmid.  
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 The mutant and wild-type SSO genes were encoded on a pQE-30 
plasmid, which is typically not compatible for use in BL21 (DE3) cells. The pQE-
30 plasmid contains a T5 promoter, which is recognized the general E. coli RNA 
polymerase.12 The pET plasmids typically used within our labratory contain a 
T7 promoter, and the BL21 (DE3) cells contain a plasmid harboring an IPTG-
inducible gene for the T7 RNA polymerase. These two plasmids create an 
inducible system that is orthogonal to the host protein expression 
machinery.12,13 Because the pQE-30 plasmid does not contain an inducible 
RNA polymerase, but relies on the host RNA polymerase, constitutive 
expression of the gene of interest occurs. This system is not properly inducible 
since there are no repressors preventing expression of the gene of interest. To 
prevent this leaky gene expression and create an inducible system, a pREP4 
plasmid can be co-transformed with the pQE-30 plasmid. Multiple pREP4 
plasmids in each cell produce large amounts of lac repressor protein which 
prevent expression of the gene of interest (Figure 3).13  
Initially, SSO WT was expressed with pREP4 by mixing the two plasmids 
together and transforming 1 μL of the solution into BL21 (DE3) cells. The SSO 
WT protein was expressed in good yield from this preparation (data not shown). 
Next, the SSO mutants were expressed containing the unnatural amino acid 
Figure 3.3: Cartoon of the pREP4 and pQE-30 system. The lac repressor protein synthesized from pREP4 
binds to the lac operon on the pQE-30 plasmid to prevent expression of the mutant SSO protein. 
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pAzF without pREP4. The mutant proteins required the Mj synthetase and Mj 
tRNA to incorporate the UAA, so the SSO mutants could not be fully expressed 
before the synthetase system had been induced. Theoretically, the synthetase 
repressor/inducer system could act as repressors and inducers for the SSO 
mutants, preventing the expression of full length SSO until the arabinose was 
added. This theory was not supported by the SDS-PAGE of the expression. 
The yield of the mutant proteins was much lower when compared to the WT 
yield, confirming the need for the pREP4 plasmid in the mutant expressions.  
Out of a desire to maintain pure stocks of the SSO plasmids while 
accommodating the need for the pREP4, SSO WT plasmid was co-transformed 
with pREP4 plasmid. This preparation was then expressed alongside a 
negative control to determine if this method would result in similar protein yield 
to the previous expression of SSO WT with pREP4. Transforming the SSO WT 
Figure 3.4: SSO WT expressed with pREP4 or without pREP4. The pREP4 was either mixed with the SSO 
WT before transformation into cells (w/ pREP4), co-transformed with the SSO WT (+ pREP4) or not 
transformed into the cells at all (-pREP4). Each sample was loaded at three different volumes (15, 10 or 6 
µL) to obtain a clear band of protein. 
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with the pREP4 
resulted in identical 
yields to the previous 
preparation of SSO 
WT, while the 
expression of SSO 
WT without the 
pREP4 plasmid 
resulted in very little 
protein (Figure 3.4). This indicates that transforming the SSO plasmid with the 
pREP4 plasmid is a viable alternative to mixing the SSO and pREP4 plasmids 
prior to transforming. This result was then examined on the three SSO mutants, 
which were expressed by triple transformation with the pREP4, synthetase 
plasmid and the SSO mutant plasmid (Figure 3.5). Only the SSO 116 mutant 
seemed to exhibit an increase in yield, but it is difficult to tell without direct SDS-
PAGE analysis of the two expressions. The SSO WT and mutant proteins were 
then subjected to a carboxylase assay as described by Park et al. to determine 
their kinetic constants. To date the reproducibility of these assays has been 
questionable, and current work is working on optimizing the assay using SSO 
WT. 
Thus, we have expressed SSO Est containing surface exposed pAzF in 
three different locations. In the future, this assay will be optimized and kinetic 
Figure 3.5: SSO WT and SSO mutants expressed with pREP4. 
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parameters for the wild type and each mutant will be obtained. Provided the 
SSO mutants kinetic constants are similar to those of the SSO WT, the mutants 
will be immobilized onto sepharose resin using a CuAAC or Glaser-Hay 
reaction as described in the previous chapter. The immobilized protein will then 
be assayed to determine its kinetic parameters. Provided the kinetic parameters 
are similar enough to ensure that the enzyme is still functioning the same way 
as the WT, further optimization of the immobilization reaction and activation 
conditions will occur using microwave technology. 
Materials and Methods 
General: The SSO P1 Carboxylesterase plasmid was obtain from the lab of 
Robert Kelley at NCSU. All PCR was performed a BioRad icycler, with the Quik-
Change II kit. All assays were performed on a synergy HT microplate reader. 
Quik-Change PCR Protocol: A pQE-30 plasmid harboring SSO Est P1 
carboxyl esterase was diluted to 24.7 ng/µL, 12.3 ng/μL, and 6.2 ng/μL. The 
PCR reaction mixture contained one of the dilutions of the plasmids (1 μL), 10 
mM DNTPs (1 μL), KAPA Hi-Fi Polymerase (1 unit/ μL, 1 μL), forward primer 
(10 μM, 1 μL), reverse primer (10 μM, 1 μL), KAPA buffer (5 μL), and Milliq 
water (40 μL). The reaction mixture was subjected to the following heating 
protocol: 95 ˚C (1 min); eighteen cycles of melting (95 ˚C, 30 s), annealing (55 
˚C, 30 s), and extension (68 ˚C, 6 min); a final extension period (68 ˚C, 6 min) 
and then held at 4 ˚C. Next the parent plasmid was digested and the mutant 
plasmid was ligated by adding 2 μL of DPN1 [20,000 units/μL], T4 Ligase buffer 
47 
 
(4 μL, 5x) and T4 Ligase (1 μL). The mixtures were then subjected to the 
following heating protocol: 37 ˚C 2 h and heat deactivation (80 ˚C, 15 min). The 
reaction was transformed (2 μL) into BL21 DE3 Escherichia coli cells by heat 
shock. The transformed cells were plated (500 μL) onto agar containing 
ampicillin and incubated at 37 ˚C overnight. The resulting cells were 
miniprepped using IBI High Speed Plasmid Mini Kit. The resulting plasmids 
were analyzed for successful insertion of the TAG mutation by sequencing at 
Genewiz. The primers were obtained from IDT DNA Technologies Inc. and are 
as follows: Y90TAG 5’-TGT AAT AGG CGA TGT GGA ATC TTA GGA CCC 
ATT ATG TAG AG-3' (forward) and 5'-CTC TAC ATA ATG GGT CCT AAG ATT 
CCA CAT CGC CTA TTA CA-3' (reverse), Y116TAG: 5'- CTA TAG GTT AGC 
TCC AGA ATA GAA GTT TCC TTC TGC AGT-3' (forward) and 5'-ACT GCA 
GAA GGA AAC TTC TAT TCT GGA GCT AAC CTA TAG-3' (reverse), 
Y191TAG 5'-CAA GAT CCA TGA TAG AGT AGT CTG ATG GGT TCT TCC T-
3' (forward) and 5'-AGG AAG AAC CCA TCA GAC TAC TCT ATC ATG GAT 
CTT G-3’ (reverse). The sequencing primer was 5’-TTC TGC TGA GCG GAT 
AAC-3’. 
Expression and Purification of SSO: A pQE-30 plasmid harboring a variable 
SSO Est TAG mutant (0.33 μL) was co-transformed with a M15 pREP4 plasmid 
(0.33 μL) and a pEVOL-pCNf plasmid (0.33 μL) into BL21 (DE3) cells using an 
Eppendorf eporator electorporator. The cells were then plated and grown on LB 
agar in the presence of chloramphenicol (0.034 mg/mL), ampicillin (0.05 
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mg/mL) and kanamycin (0.01 mg/mL) at 37 ̊ C overnight. One colony was then 
used to inoculate LB media (4 mL) containing amplicillin, chloramphenicol and 
kanamycin. The culture was incubated at 37  ̊C overnight and used to inoculate 
an expression culture (10 mL LB media, 0.05 mg/mL Amp, 0.034 mg/mL Chlor, 
0.01 mg/mL Kan) at an OD600 0.1. The cultures were incubated at 37 ̊ C to an 
OD600 between 0.6 and 0.8 at 600 nm, and protein expression was induced by 
addition of pAzF (100 L, 100 mM) and 20 % arabinose (10 L) and 0.8 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG; 10 L). The cultures were allowed 
to shake at 30 ̊ C for 16-20 h then centrifuged at 5,000 rpm for 10 minutes and 
stored at -80 ̊ C for 3 hours. The cell pellet was re-suspended using 500 µL of 
Bugbuster (Novagen) containing lysozyme and 200 μL Lysis buffer. The 
mixture was incubated at 37 ̊ C for 20 minutes. The solution was transferred to 
an Eppendorf tube and centrifuged at 15,000 rpm for 10 minutes. The 
supernatant was then incubated at 80 ˚C for 10 minutes and centrifuged at 
15,000 rpm for 10 minutes. Purified SSO Est was analyzed by SDS-PAGE 
(10%) and employed without further purification. Protein concentrations were 
determined by UV-Vis absorbance at 280 nm. 
Arylesterase Assay: The reaction mixture was prepared in triplicate by adding 
2 μL of SSO Est TAG variant protein to a mixture of 76 μL of 100 mM Acetate 
buffer, 4 μL of 4-nitrophenol-hexanoate (0.14 g/mL), and 18 μL of 1x PBS (pH 
7.2). A control mixture was also made in triplicate, which did not contain protein. 
The control and reaction mixtures were incubated at 70 ˚C for 10, 20 or 30 
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minutes, then an absorbance reading was taken at 405 nm to measure the 
initial product formation. The reaction was quenched with 100 μL of distilled 
water saturated with Na2CO3and another reading was taken at 405 nm.4 
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Chapter 4: Initial Steps Towards a Novel 
Prostate Cancer Test 
Prostate cancer (PCa) is an extremely common cancer in the male 
population. The most common method of detecting cancerous changes in the 
prostate is an assay that quantitates the concentration prostate-specific antigen 
(PSA) present in the blood stream. This test is somewhat unreliable, as it often 
yields false positives which necessitate the use of invasive biopsies to 
ultimately diagnose cancer.1 A modified version of Ubiquitin like protease 1 
(Ulp1) can be used to develop a more accurate and less invasive test for PCa. 
Ulp1 is a yeast protease that cleaves small ubiquitin-like modifier (SUMO) from 
other cellular proteins.2,3 Cancerous cells are characterized by abnormal gene 
expression and unusual levels of post translational modifications, such as 
abnormally SUMOylated proteins.4 For instance, a tumor suppressor gene 
known as reptin is highly SUMOylated in metastatic prostate cancer cells.5 This 
difference in SUMOylation between healthy and cancerous cells provides a 
unique opportunity to develop a non-invasive method of screening patient 
samples for cancerous changes. This SUMO based assay would use cell-
penetrating peptides (CPPs) to deliver a fluorescently labeled, non-catalytic 
form of Ulp1 (Utag) into patient cells, where the fluorescent Utag would bind to 
SUMO-protein conjugates. The patient cells could then be compared to control 
cells to assess the relative levels of protein SUMOylation. High amounts of 
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SUMOylation, indicated by localized fluorescence, would indicate a cancerous 
sample. This test could be performed on cells that are normally secreted from 
the prostate, allowing doctors a chance to screen men who received a false 
positive from the PSA test. 
SUMO, like Ubiquitin (Ub), is a human protein that is involved in post-
translational modification of other cellular proteins to regulate cellular pathways. 
Both Ub and SUMO are conjugated to other proteins via an isopeptide linkage 
between a lysine on the target protein and the C terminus of Ub or SUMO. 
Unlike Ub, SUMO is not primarily utilized to degrade proteins. For instance, the 
yeast analog of human SUMO (Smt3, Figure 4.1A and 4.1B, blue) is used to 
modulate cellular localization and transcription factor stability.3  
Like Ub, SUMO is regulated by other cellular proteins. Ulp1 is one such 
protein, it cleaves the target protein lysine-SUMO/Smt3 C terminus isopeptide 
bond following the SUMO Gly-Gly motif.2,3 The C-terminal region of Ulp1 is used 
to bind and cleave SUMO linked peptide bonds, and the N-terminus is utilized 
by the cell to regulate Ulp1 activity. The C-terminal region was cocrystallized by 
Figure 3.1: Ulp1 (purple) and Smt3 (blue) with the GG motif highlighted in cyan (A) the hydrophobic tunnel 
highlighted in orange (B) the catalytic triad highlighted in green (C) SUMO/Smt3 interacting motifs of Ulp1 
highlighted in various colors. 
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Mossesova and Lima with Smt3, where the details of the Smt3-Ulp1 interface 
where revealed. Ulp1 maintains its selectivity for SUMO by recognizing the -
GGX C terminal sequence (Figure 4.1A, cyan). This sequence must be 
threaded through a hydrophobic tunnel to access the active site. This tunnel is 
created by residues Trp-448 and Trp-515, with the catalytic triad at the end 
(Figure 4.1A, orange).3 This tunnel interacts with the GGX sequence via van 
Der Waals (VDW) contacts between the α carbon of the glycines and the amino 
acids in the tunnel, except for the cysteine. Trp-448 acts as a clamp, holding 
down the GG motif. This GG recognition domain is relatively small when 
compared to those of Ub processing enzymes, which allows Ulp1 to cleave 
SUMO from large protein conjugates without affecting their structure.3 Multiple 
non-covalent interactions, such as salt bridges and VDW contacts are 
employed in the six SUMO interaction motifs to keep SUMO and Ulp1 spatially 
close in order to facilitate recognition of the GG motif. 
The catalytic function of Ulp1 is accomplished by a catalytic triad (Figure 
4.1B, green) where Cys-580 is coordinated to a basic His-514 which is 
stabilized by Asp-531. Gln-574 Nε and Cys-580 N (Figure 4.1B, green) stabilize 
the transition state by providing an oxyanion hole.3 A truncated version of Ulp1, 
known as Utag, lacks C-580 and is not capable of cleaving SUMO from other 
proteins. This lack of catalytic activity makes Utag the ideal protein for the 
development of a SUMO-based cancer diagnostic.  
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 There are two main challenges in developing this novel diagnostic. One, 
the Utag must be easily detectable in vivo, and two, the Utag must be able to 
enter cells. The first challenge can be overcome by expressing Utag containing 
a surface-exposed UAA.  The UAA containing Utag could then be subjected to 
bioconjugation reactions to couple it to a fluorophore. This chapter will focus on 
the optimization of the UAA containing Utag expression and subsequent 
fluorophore conjugation. Two isoforms of Utag, one from S. cerevisiae and one 
form Kluyveromyces marxianus (Km), will be utilized in this optimization. The 
Km Utag is a heat stable mutant, and so it is a few amino acids smaller and 
folded more tightly that the Sc Utag. Both the Sc Utag and the Km Utag will be 
expressed as fusion proteins with maltose- binding protein (MBP), as this fusion 
helps to stabilize the expressed Utag. The mechanism of importing the Utag 
complex will be discussed briefly in the conclusion, as this mechanism will be 
studied and optimized in the future. 
Results and Discussion 
Surface exposed tyrosine residues on S. cerevisiae Utag were selected for 
mutation. S. cerevisiae Utag Y147TAG (Sc 147), S. cerevisiae Utag Y241TAG 
(Sc 241), S. cerevisiae Utag Y253TAG (Sc 253) mutants were prepared using 
Quik-Change PCR site directed mutagenesis. K. marxianus Utag Y576TAG 
(Km 576) and K. marxianus Utag Y147TAG (Km 147) were prepared using Q5 
PCR. Sc 147 exhibited the most differential growth relative to a negative control 
under conditions using a template plasmid concentration of 12.3 ng/μL and an 
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annealing temperature of 68 ˚C. Sc 241 and Sc 253 did not exhibit differential 
growth when subjected to the concentration gradient QuikChange, but did 
exhibit differential growth after the annealing temperature gradient 
QuikChange. Sc 241 exhibited the most differential growth at 53 ˚C and 55 ˚C 
and Sc 253 exhibited the best differential growth at 53 ˚C and 61 ˚C. The Sc 
241 and Sc 253 plasmids will be sequenced in the future for successful insertion 
of the TAG mutation.  
Wild type (WT) Utag containing the TAG mutation was expressed in 
duplicate using pEVOL WT at 30 ˚C. This pEVOL WT plasmid incorporates a 
standard tyrosine residue in place of the TAG mutation. Several conditions were 
examined, including one where the log-phase cells were pelleted and 
resuspended in one-fifth the original volume of media prior to adding IPTG to 
induce Utag expression. Another expression was treated normally, without 
Figure 4.2: Expression levels of Sc Utag 147 using pEVOL WT as the synthetase when the induction 
media is concentrated (+ Spin) or not concentrated (- Spin). 
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pelleting the cells. This was performed to optimize the expression and assess 
if the concentration protocol could be employed to minimize the amount of UAA 
needed for each expression. The pelleted expression yielded less protein than 
the non-concentrated expression, so the induction solution was not 
concentrated during expression of Utag mutant proteins from this point on 
(Figure 4.2). Having optimized the expression conditions, Sc Utag 147 and Km 
Utag 147 was expressed containing para-azidophenylalanine (pAzF, 1) using 
pEVOL-pCNF.  The resulting protein was subjected to a click reaction with an 
alkyne-linked fluorophore, alongside a GFP positive control and a Utag WT 
negative control (Scheme 4.1). The reaction was analyzed by SDS-PAGE. No 
fluorescence was observed, but the proteins did stain with coomassie blue, 
58 
 
indicating that the reaction did not work. After a several unsuccessful attempts 
to perform the click reaction, the Sc 147 and Km 147 were then expressed with 
para-propargyloxyphenylalanine (pPrF, 2) instead of pAzF.  The Utag + 2 
mutants were then successfully reacted with the alkyne fluorophore via a 
Glaser-Hay reaction (Figure 4.3). The presence of fluorescent bands at the 
weight of the protein indicate that the fluorophore is covalently bound to the 
protein at the pPrF residue, confirming the successful incorporation of the UAA. 
The slight fluorescence in the Utag WT negative control lane is likely due to 
non-covalent interactions that have trapped a small amount of the fluorophore 
Scheme 4.1: Structure of the unnatural amino acids pAzF (1), pPrF (2) and coumarin (3) along with the 
products of the reactions they are utilized in. 1 is utilized in the CuAAC reaction to yield a 1,4 linked 1,2,3-
triazole (4) and 2 is utilized in the Glaser-Hay reaction to yield a diyne (5). 
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with the protein. The lack of any fluorescence or protein in the GFP positive 
control lane is unusual, as this Glaser-Hay reaction was optimized for GFP, but 
it doesn’t necessarily indicate that the Glaser-Hay reaction was unsuccessful. 
Instead it appears based on the coomassie stained gel that there was no 
appreciable GFP in the reaction to be labeled.  
This fluorescently labeled Utag mutant was then assayed for SUMO 
binding ability via three types of pull-down assay. First, the fluorescently labeled 
Sc Utag 147 was incubated with a previously prepared Western blot membrane 
that had SUMO bound. The membrane was then analyzed by UV-irradiation to 
detect the fluorophore; however, no detectable fluorescence was observed. 
This may be due to the low concentration of the fluorescently labeled Sc Utag 
147 in the loading solution.  
The second pull-down assay utilized agarose beads with SUMO 
immobilized on the surface. These beads were incubated with the WT Utag and 
Figure 4.3: Glaser-Hay reaction between alkyne fluorophore and either GFP + 2, Sc 147 + 2, or Sc WT. (A) 
SDS-PAGE of the Glaser-Hay stained with coomassie and (B) the fluorescent scan of the SDS-PAGE, where 
the presence of a fluorescent band indicates successful conjugation between the fluorophore and the 
protein. 
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fluorescently labeled Sc Utag 147 to allow the Utag to bind to the SUMO. The 
beads were washed and imaged on a Biorad gel imager in eppendorf tubes 
with 20 μL of PBS and in a 96-well plate in a Synergy plate reader with 70 μL 
of PBS. Neither imaging system showed a difference in fluorescence between 
the wild type and the fluorescently labeled Sc Utag 147. Once again, this is 
likely because there wasn’t enough fluorescently labeled Sc Utag 147 bound to 
visualize or detect in such a dilute solution.  
Finally, a plate-based pull-down assay was performed by immobilizing 
SUMO onto the bottom of a 96-well plate using poly-L-lysine, then allowing the 
negative control Utag WT, the fluorescently labeled Sc Utag 147 and 
fluorescently labeled Km fluorescently labeled Utag 147 to bind to the SUMO. 
The plate was then read at 485 nm to determine the presence of the 
fluorophore. The WT Utag and the fluorescently labelled mutants did not exhibit 
any difference in fluorescence, indicating that this assay was not successful in 
binding the either mutant of the fluorescently labeled Utag 147.  
The bead based assay was then adapted to be used with SDS-PAGE, 
as the SDS-PAGE would make it possible to visualize both the wild type and 
the mutant protein, giving us positive control for the binding assay. The assay 
was performed as before with WT Utag, fluorescently labeled Sc 147 and 
fluorescently labeled Km 147. Instead of analyzing the assay via fluorescence, 
the Utag was cleaved from the bead by denaturing it with 0.2% SDS. The 
resulting SDS-protein solution was then analyzed for fluorescence in a 96-well 
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plate. This did not yield any difference in fluorescence, so the protein was 
further analyzed by SDS-PAGE. Neither the WT nor either of the mutants bound 
to the SUMO, possibly because the fluorophore’s bulk or Glaser-Hay conditions 
were interfering with the folding of the protein. Since the WT protein was also 
subjected to the Glaser-Hay, the reaction conditions may have interfered with 
its ability to bind as well. To alleviate any decrease in binding ability originating 
from the Glaser-Hay, the Km 147 was expressed containing a fluorescent 
amino acid (coumarin, 3) with pEVOL-Cou (Figure 4.4). This mutant protein 
also didn’t bind to SUMO, leading to 
the conclusion that UAA incorporation 
at this position interfered with the 
SUMO binding ability of the mutants. In 
light of this conclusion, the Y147TAG 
mutants were not used again and further experiments focused on the Km 
Y576TAG mutant.  
Figure 4.4: Expression of Km 576 + 3 and Km 576 
+ 1 along with a Km WT control. One lane was 
omitted from this gel for clarity. 
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 Km 576 was expressed with 2 and subjected to a Glaser-Hay coupling 
with an alkyne fluorophore. Unfortunately, this Utag mutant did not bind SUMO 
either, as evidenced by the lack of protein in the elution lane. The fluorescently 
labeled Km 576 didn’t seem to bind to SUMO at all, as the bead loading solution 
contained a substantial amount of protein (Figure 4.5).  To test if the Glaser-
Hay conditions or addition of the fluorophore was interfering with the ability of 
Km 576 to bind SUMO, Km 576 was 
expressed with 3 and 1. Wild type Km 
Utag was also expressed as a positive 
control. The coumarin incorporation 
was confirmed by fluorescence 
analysis in a fluorimeter. The presence 
of coumarin is detectable by a peak at 
450 nm, as is seen in the Km 576 + 3 
mutant, indicating that the UAA 
incorporation was successful 
(Figure 4.6).6 The expressed 
proteins were then assayed for 
their ability to bind SUMO 
(Figure 4.7). Only the Utag WT 
bound SUMO, as indicated by the presence of a band in the elution lane. No 
protein was detected in the elution lanes of the mutants, meaning that the 
mutants are incapable of binding SUMO. Different volumes of each protein 
Figure 4.5: SUMO binding assay of Km 576 + 2 
conjugated to fluorophore via a Glaser-Hay (GH) 
reaction. No protein eluted from the SUMO beads, 
and a significant amount of protein was left in the 
bead loading solution. This indicates that the Utag 
did not bind to the immobilized SUMO. 
Figure 4.6: Fluorescence Spectra of Km WT and Km 576 + 
3. 
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were also run on the gel fluorescently labeled to quantitate the amount of 
protein that bound to the SUMO. The 25% lanes were loaded with one-quarter 
the volume of each protein added to the bead loading solutions, and the 50% 
lanes were loaded with half the volume of the specific protein added to the bead 
loading solution.  The presence of two bands in the wild type lanes revealed 
that two sizes of the Utag WT were being expressed.  The larger protein was 
the full-length Utag which bound SUMO. The smaller protein was a truncated 
version of Utag which did not bind SUMO. This smaller size was the same size 
as the mutant proteins, indicating that most of the mutant protein that had been 
expressed was a truncated form of Utag. This truncation was likely the reason 
none of the mutant proteins were binding SUMO. 
It is unlikely that this truncation happened at the amber stop codon, since 
the non-mutated wild type protein and the mutant protein were both the same 
Figure 4.7: Binding Assay of Km 576 mutant proteins. Protein in the elution lanes indicate that the Km 
mutant bound to the bead immobilized SUMO and was eluted via SDS denaturation. The indicated 
percentage on the lanes indicates the percentage of the protein loaded onto the beads. 
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size. The successful Glaser-Hay reactions and the confirmation of coumarin 
incorporation also support the hypothesis that this truncation did not happen at 
the amber stop codon. If the translation machinery had read the amber stop 
codon as a regular stop codon and truncated the protein at position 576, the 
UAAs would not be incorporated. Since Utag is a yeast protein, it is likely that 
the difference in codon bias between the two organisms is responsible for the 
truncated Utag. Codon bias is the tendency of an organism to preferentially use 
one of the codons for an amino acid over other codons for the same amino acid. 
For instance, yeast typically use AGA for arginine, while E. coli use other 
codons for arginine.7,8 Because of this tendency, yeast cells synthesize more 
tRNAs containing AGA than bacteria do. These tRNAs that are not usually 
synthesized in bacteria are called rare tRNAs in the context of bacterial protein 
expression. When Utag expression is induced in E. coli, the bacteria use up all 
the available rare tRNAs before the protein is fully synthesized, resulting in the 
truncated protein we observe.  To correct for this codon bias, a pRIL plasmid 
was introduced to the expression system. The pRIL plasmid encodes the genes 
for rare tRNA synthesis, allowing the bacteria to make the tRNAs necessary to 
synthesize a heterologous protein. This pRIL plasmid is under chloramphenicol 
selection, so a different synthetase plasmid was also introduced to the 
expression system. The new synthetase plasmid contains the same pCNF 
synthetase in a different plasmid backbone that is under spectinomycin 
selection. The pRIL plasmid was transformed into E. coli cells which were made 
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electrocompetent to facilitate facile transformation with the protein and 
synthetase plasmids. Using this new three plasmid expression system, Km 576 
+ 1 was expressed and 
subjected to the SUMO 
binding assay. Again, the 
mutant did not bind SUMO, 
although it was nearly the 
same size as the Km Utag 
WT (Figure 4.8). This indicates that the bacteria were able to synthesize nearly 
all of the mutant Utag before running out of tRNAs, and that more optimization 
of the expression protocol is needed.  
To encourage expression of full-length Utag, the three-plasmid 
expression system was used to express Km 576 + 2 and Km Utag WT at 18 ˚C 
Figure 4.8: Binding assay of Km WT from Kerscher lab and 
Km 576 + 1 from three plasmid expression at room 
temperature. 
Figure 4.9: Binding assay of Km WT obtained from Kerscher lab (KL) as well as Km 
WT and Km 576 + 2 from three plasmid expression at 18 ˚C in 1% glycerol. 
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in induction media containing 1% (v/v) glycerol. The cooler temperature and 
IPTG-glycerol combination slow the growth rate of the E. coli.9 Slowing the 
growth of the cells means that the cells can devote more resources to synthesis 
of a full-length protein instead of to reproducing themselves. These proteins 
were assayed for their SUMO binding ability alongside a positive control of full-
length Km WT obtained from the lab of Oliver Kerscher. The Km WT from 
Kerscher lab and Km WT the triple plasmid expression system bound SUMO, 
but the Km 576 + 2 did not bind SUMO (Figure 4.9). The protein expressed with 
the new method is full length, so Km 576 is likely not a good position for amber 
suppression, since UAA incorporation appears to interfere with the folding or 
another mechanism that is responsible for SUMO binding.  
Considering, the difficulties present in expressing suitable Utag protein 
containing a UAA, the amber stop codon was moved to sites in the maltose 
binding protein (MBP) that is fused with both the Sc Utag and Km Utag genes. 
Q5 PCR was used to generate two MBP mutants, MBP Y99TAG and MBP 
Y341TAG. These plasmids, along with the previously generated Sc 241 and Sc 
253, will be sequenced to confirm the TAG mutation, then expressed with a 
UAA and assessed for SUMO binding ability. Additionally, another Km Utag 
mutant, Km S406TAG, will be generated and assayed for SUMO binding ability.  
We have shown that it is possible to site specifically incorporate an 
unnatural amino acid into full length Km Utag mutants and into truncated Sc 
Utag mutants using a three-plasmid system induced at 18 ˚C in 1 % glycerol. 
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In the future, these findings will be extended to produce a full length Utag 
protein with an unnatural amino acid incorporated either directly into the Utag 
or into its fusion protein, MBP. This construct will then be expressed in a fusion 
with a CPP to facilitate its uptake into cells. This complex will be subjected to a 
Glaser-Hay reaction to conjugate it to a fluorophore so the complex can be 
tracked though the cell. This protein complex will then be incubated with 
mammalian cells, where the CPP will facilitate uptake of the complex and the 
complex will bind to SUMO in vivo. Further optimization will allow this complex 
to be developed into a robust diagnostic tool to identify cancerous cells in 
prostate cell samples.  
Materials and Methods 
General: All reagents were obtained from Acros, USB, Biotium, Alfa Aesar, 
Sigma Aldrich or Amresco and used without further purification unless noted. 
Unnatural amino acids were prepared according to literature protocols.10 
Protein and DNA gels were analyzed using a Bio-Rad gel imager (Bio-Rad 
Molecular Imager Gel Doc XR+). 
Quik-Change PCR: This protocol was carried out on a Biorad icycler, with the 
Quik-Change II kit. A pET plasmid harboring a MBP-Utag fusion was diluted to 
24.7 ng/µL, 12.3 ng/μL, and 6.2 ng/μL. The PCR reaction mixture contained 
one of the dilutions of the plasmids (1 μL), 10 mM DNTPs (1 μL), KAPA Hi-Fi 
Polymerase (1 unit/ μL, 1 μL), forward primer (10 μM, 1 μL), reverse primer (10 
μM, 1 μL), KAPA buffer (5 μL), and Milliq water (40 μL). The reaction mixture 
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was subjected to the following heating protocol: 95 ˚C (1 min); eighteen cycles 
of melting (95 ˚C, 30 s), annealing (55 ˚C, 30 s), and extension (68 ˚C, 6 min); 
a final extension period (68 ˚C, 6 min) and then held at 4 ˚C. Next the parent 
plasmid was digested and the mutant plasmid was ligated by adding 2 μL of 
DPN1 [20,000 units/μL], T4 Ligase buffer (4 μL, 5x) and T4 Ligase (1 μL). The 
mixtures were then subjected to the following heating protocol: 37 ˚C 2 h and 
heat deactivation (80 ˚C, 15 min). The reaction was transformed (2 μL) into 
BL21 DE3 Escherichia coli cells by heat shock. The transformed cells were 
plated (250 μL) onto agar containing ampicillin and incubated at 37 ˚C 
overnight. The resulting cells were miniprepped using IBI High Speed Plasmid 
Mini Kit. Alternately, the pET-Utag plasmid was used at 12.3 ng/μL and a heat 
gradient was used instead of the concentration gradient. In the heat gradient 
version of the protocol, all procedures are the same except the annealing 
temperature was 53 ˚C, 55.1 ˚C, 61.3 ˚C, or 63 ˚C and all reactions contained 
12.3 ng/μL of parent plasmid. The resulting plasmids were analyzed for 
successful insertion of the TAG mutation by sequencing at Genewiz. The 
primers were obtained from IDT DNA Technologies Inc. and are as follows: Sc 
Y147TAG 5’-CCG GAC GCC TTG CTA ACC CCT TTC TGA TAA ATT G-3’ 
(forward), 5’-CAA TTT ATC AGA AAG GGG TTA GCA AGG CGT CCG G-3’ 
(reverse); Sc Y241TAG 5’-ACA TAT ATT CCA CTG TCC TAG CCA TTT GGT 
TGC TGC-3’ (forward), 5’-GCA GCA ACC AAA TGG CTA GGA CAG TGG AAT 
ATA TGT-3’ (reverse); Sc Y253TAG 5’-GGC GCA TCT GCA CTT CCC TAG 
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AGA GTA TTC ATA CAA AC-3’ (forward), 5’-GTT TGT ATG AAT ACT CTC 
TAG GGA AGT GCA GAT GCG CC-3’ (reverse).  
Q5 PCR: This protocol was carried out on a thermocyler (Applied Biosystems 
2720 Thermocycler) with the Q5 Site Directed Mutagenesis Kit (New England 
Biolabs). A pET plasmid harboring a MBP-Utag fusion was diluted 1:10, 1:100, 
1:1000. The PCR reaction mixture contained one of the dilutions of the plasmids 
(1 μL), forward primer (10 μM, 1.25 μL), reverse primer (10 μM, 1.25 μL), Q5 
Hot Start Master Mix (12.5 μL), and Milliq water (9 μL).  The reaction mixture 
was subjected to the following heating protocol: 98˚C (30 s); eighteen cycles of 
melting (98˚C, 10 s), annealing (60-70 ˚C, 30 s), and extension (72 ˚C, 8 min); 
a final extension period (72 ˚C, 10 min) and then held at 4 ˚C. The annealing 
temperature was changed to match the annealing temperature of the primers 
for each reaction. Next the parent plasmid was digested and the mutant DNA 
was circularized using the Q5 Site Directed Mutagenesis Kit (New England 
Biolabs). The reaction was transformed (5 μL) by heat shock into NEB 5-α 
competent Escherichia coli. The transformed cells were plated (15, 60, 120 μL) 
onto agar containing ampicillin and incubated at 37 ˚C overnight. The resulting 
cells were miniprepped using IBI High Speed Plasmid Mini Kit. The resulting 
plasmids were analyzed for successful insertion of the TAG mutation by 
sequencing at the William and Mary Molecular Core Facility. The primers were 
obtained from IDT DNA Technologies Inc. and are as follows: Km Y576TAG 5’-
TAG AGC CTA GAT TTC AAT GCA CAA GAT GCG GTT AAT ATG- 
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3’(forward), 3’-AT TTT TGC TCA TAT AAA GAG TAT TCA AGC AAA CGT ATA 
TTC-5’ (reverse); Km S406TAG 5’-TAG GTC AGT TTC TTA ATA ATG AAG 
AAC ATT CAG TCA TAT TTG-3’ (forward), 3’-A TTT GCT CCC GAA GAG AGC 
GAA TCA AGA TAT AAT ATC CTT TTA TTT TTG-5’ (reverse); MBP Y341TAG 
5’- TAG GCC GTG CGT ACT GTG ATC AAC GCC GCC AGC-3’ (forward), 3’- 
CCA GAA AGC GGA CAT CTG CGG GAT GTT CGG CAT G-5’ (reverse); MBP 
Y99TAG 5’- AAC GGC AAG CTG ATT ATT GCT TAC CCG ATC GCT-3’ 
(forward), 3’- CTA ACG TAC GGC ATC ATC CCA GGT AAA CGG ATA C-5’ 
(reverse). 
Expression and Purification of Protein: A pET plasmid harboring a variable 
MBP-Utag fusion mutant (0.5 μL) was co-transformed with a synthetase 
plasmid (pEVOL-pCNF unless stated, 0.5 μL) into BL21 (DE3) cells using an 
Eppendorf eporator electorporator. The cells were then plated and grown on LB 
agar in the presence of chloramphenicol (0.034 mg/mL), ampicillin (0.050 
mg/mL) at 37  ̊C overnight. One colony was then used to inoculate an aliquot 
of LB media (5 mL) containing ampicillin and chloramphenicol. The cultures 
were incubated at 37 ̊ C overnight and used to inoculate an expression culture 
(100 mL LB media, 0.050 mg/mL Amp, 0.034 mg/mL Chlor) at an OD600 0.1. 
The cultures were incubated at 37  ̊C to an OD600 between 0.6 and 0.8 at 600 
nm, and protein expression was induced by addition of an unnatural amino acid 
(UAA; 1 mL, 100 mM) and 20 % arabinose (1.5 mL) and 0.8 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG; 1.5 mL). The cultures were allowed to shake at 
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room temperature for 5 h then centrifuged at 5,000 rpm for 10 minutes and 
stored at -80 ̊ C for 20 min. The cell pellet was re-suspended in SPB with 5mM 
TCEP (2 mL). The cell suspension was sonicated on ice (3 x 10 s, 1 min rests, 
30 % amplitude). The cellular debris was pelleted by centrifugation (15,000 rpm, 
8 min) and the resulting supernatant was diluted to 5 mL with SPB containing 
5mM TCEP and loaded onto Talon Metal Affinity resin (200 μL). The resin was 
washed with SPB (3 x 3 mL) and the protein was eluted with 250 mM imidazole 
in SPB (250 μL). TCEP was added to each elution and the protein was frozen 
at -80 ̊ C in 10 % glycerol.   
CuACC Reaction: The Utag + 1 mutant was thawed and buffer exchanged into 
PBS containing 1mM DTT using a molecular weight cutoff column. Tris[(1-
benzyl-1H-1,2,3-triazol-4yl)methyl]amine (TBTA; 5mM, 20 µL) was added to an 
Eppendorf tube containing 50 mM tris(2-carboxyethyl)phosphine (TCEP; 2 µL) 
and 50 mM CuSO4 (2 µL). The catalyst system was diluted in phosphate 
buffered saline solution (PBS; 6 µL) and 0.335 mg/mL of Utag-pAzF mutant (20 
µL) was added along with 1 mM Alkyne fluorophore (Fluor-488- Alkyne, 10 μL). 
This mixture was incubated at 4  ̊C for 14 h then transferred to a molecular 
weight cutoff column and washed with PBS Buffer (8 x 80 µL) and centrifuged 
at 13,200 rpm for 2 min. The reactions were then analyzed via SDS-PAGE (10 
%).  
Glaser-Hay Reaction: The Utag + 2 mutant was thawed and buffer exchanged 
into PBS containing 1mM DTT using a molecular weight cutoff column. The 
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reactants were added to a microcentrifuge tube in the following order. Copper 
iodide (5 μL, 500mM) was added to 0.335 mg/mL Utag-pPrf (15 μL). Next 
N,N,N′,N′-Tetramethylethylenediamine (TMEDA; 500 mM, 2 μL) and 1 mM 
alkyne fluorophore (Flur-488-Alkyne, 10 μL) and PBS (8 μL) were added to the 
reaction. The reaction was incubated at 4 ˚C for 4 h then transferred to a 
molecular weight cutoff column and washed with PBS Buffer (8 x 80 µL) and 
centrifuged at 13,200 rpm for 2 min. The reactions were then analyzed via SDS-
PAGE (10%). 
Pull Down Assay on Fluorescent Labeled Utag: Bead containing 
immobilized SUMO (Boston Biochemical, rhSUMO-1 beads; 25 μL) were 
washed with SPB (1 mL). SPB (900 μL), TCEP (50 mM, 100 μL) and Utag 
variant protein (30 μL) were added to the washed beads and rotated for 30 min 
at room temperature. The beads were washed with SPB (3 x 1 mL) by pelleting 
the beads and pipetting the supernatant SPB off. The beads were resuspended 
in PBS (20 μL) and analyzed using a Bio-Rad gel imager (BioRad Molecular 
Imager Gel Doc XR+) on the SPYRO Ruby setting. The resin was also imaged 
by transferring the resin to a 96-well plate and adding PBS (50 μL). The resin 
was then analyzed on a plate reader (Biotek Synergy HT Microplate Reader). 
The protocol was set to measure the fluorescence end point after 5 s of shaking, 
at an excitation wavelength of 485 nm and an emission wavelength of 528 nm. 
Plate Pull Down Assay: Poly-L-lysine (200 μL, 0.1% w/v in water) was added 
to two wells on a 96-well plate and incubated at room temperature for 5 min. 
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The wells were emptied and allowed to dry for 5 minutes, then washed once 
with SPB (300 μL). SUMO-1 was added to the wells and the plate was rocked 
for 30 minutes. The wells were washed three times with SPB (300 μL) and 1% 
(w/v) BSA in SPB (200 μL) was added to the wells. The plate was rocked at 4 
˚C for 16 h, then the wells were washed with SPB. The variant Utag Glaser-Hay 
(10 μL) was added to 90 μL to SPB containing 5 mM TCEP. 50 μL of the diluted 
variant Utag Glaser Hay was added to the treated wells and 50 μL were added 
to untreated wells. The plate was rocked at 4 ˚C for 1 h. The wells were washed 
three times with SPB containing 5 mM TCEP (300μL) and analyzed on a plate 
reader (Biotek Synergy HT Microplate Reader). The protocol was set to 
measure the fluorescence end point excitation wavelength was 485 nm and the 
emission wavelength was 528 nm.  
Pull Down Assay: Bead containing immobilized SUMO (25 μL) were washed 
with SPB (1 mL). SPB (900 μL), TCEP (50 mM, 100 μL) and Utag variant protein 
(30 μL) were added to the washed beads and rotated for 30 min at room 
temperature. The beads were washed with SPB (3 x 1 mL) by pelleting the 
beads and pipetting the supernatant SPB off. The protein was eluted by adding 
of 2x SDS-PAGE loading dye (20 μL). The reactions were then analyzed via 
SDS-PAGE (10%). 
Fluorescence Measurement to Confirm Coumarin Incorporation: After 
purification 10 μL of the Km 576 Utag + 3 was added to a quartz cuvette and 
diluted up to 3 mL with PBS. This was then analyzed on a fluorimeter (Perkin 
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Elmer LS 55 Luminescence Spectrometer). The mixture was excited at 340 nm 
with a 10 nm slit width for the excitation wavelength and 5 nm slit width for the 
emission wavelengths. The scan speed was set at 300 nm/min. 
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Chapter 5: Functionalizing Divalent 
Bioconjugates to Multivalent Complexes  
 Bioconjugations have found a wide range of applications in modern 
science, from antibody-drug conjugations to enzyme immobilization. One 
limitation of these applications is that only two molecules can be linked together, 
limiting the complex performing to two functions. This creates a problem when 
more than two functionalities need to be incorporated into a conjugate, as in 
molecular assembly lines where a degree of multivalency is required. Molecular 
assembly lines also require controlled enzyme orientation for maximum 
efficiency. UAAs can represent a precise mechanism for the introduction of 
more complex bioconjugates to address these problems. UAAs can be site-
specifically inserted to minimize interference with the enzyme’s function and 
optimize the orientation of the protein in reference to the solid support (Figure 
5.1A).  Multivalent complexes would also be useful in medical applications, for 
instance in developing ligand-targeted therapeutics. In this system a 
Figure 5.1: Potential applications of multivalent complexes (A) molecular assembly line with proteins 
immobilized by UAAs (B) a multivalent complex with a fluorophore (yellow), a therapeutic peptide (red) and a 
targeting molecule (multicolored) conjugated together via UAAs. 
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therapeutic molecule, a fluorophore and an antibody could be complexed 
together to make simultaneous cellular targeting and tracking of the drug 
possible (Figure 5.1B). Multivalent conjugation could also be used as an 
alternate to hapten-carrier complexes in vaccines. Several small molecules 
could be conjugated together, instead of to a carrier protein, to yield an 
appropriately immunogenic molecule.  
 Multivalent reactions have been developed in organic solvents at high 
temperatures, but they have not been explored in a biological context due to a 
lack of appropriate bioconjugates. Most bioconjugations do not install 
sufficiently reactive 
linkages to allow for 
further reaction into 
a multivalent 
complex. The 1,2,3-
triazole generated 
by the CuAAC 
reaction is highly 
stable and 
unreactive, making bioconjugates containing this chemistry unsuitable for 
further reaction to create a multivalent complex. The biological Glaser-Hay 
reaction developed by Lampkowski et al. is unique in this respect, as it results 
in an electron dense diyne linkage that affords further reaction to create 
Figure 5.2: A divalent diyne functionalized into multivalent complexes. 
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multivalent complexes. Figure 5.2 illustrates some organic reactions that result 
in multivalent complexes, which theoretically can be optimized to perform under 
physiological conditions. One such reaction is a reaction between a diyne and 
an amine. This reaction was developed in an organic context by Sun and 
colleagues using cyclic amines such as pyrrolidine (Scheme 1A). This reaction 
will be optimized for biological conditions in this chapter. 
Results and Discussion 
 To replicate the literature protocol, 1,4-diphenylbuta-1,3-diyne (1) and 
hexa-2,4-diyne-1,6-diol (2) were synthesized using a Glaser-Hay reaction. 1 
was successfully reacted at 80 ˚C using pyrrolidine as a solvent to create 3 and 
analyzed by 1H NMR (Scheme 5.1A). To test the protocol at physiological 
Scheme 5.1: Cyclic amine mediated multivalent reaction on a diyne (A) as described by Sun et al. (B) under 
biological conditions.1 
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temperatures, 1 was reacted, still using pyrrolidine as a solvent, at 37 ˚C for 24 
h. This reaction was also successful, so the reaction was tested in aqueous 
solvent. For this reaction, 2 was synthesized to overcome 1’s lack of aqueous 
solubility. 2 was reacted at room temperature in 10% DMSO in water, a more 
physiologically appropriate solvent than pyrrolidine. The product was analyzed 
by mass spec to confirm the presence of 4, indicating that the reaction was 
successful (see experimental). Since this reaction was working under 
physiological conditions, this methodology was extended to a more biologically 
relevant context using GFP (Figure 5.3). GFP was expressed containing para-
propargyloxyphenylalanine (pPrF, 5), and 
reacted with the immobilized alkyne moiety 
by a biological Glaser-Hay (Figure 5.4).3 
Aminofluorescein was incubated with the 
resin and copper for 6 h. The resin was then 
washed and analyzed by UV-irradiation on 
Figure 5.4: The unnatural amino acid 
incorporated into GFP, pPrF, which contains 
the alkyne functionality utilized in the Glaser-
Hay reaction. 
Figure 5.3: Multivalent reaction with immobilized GFP and 5-Aminofluorescein (red star). 
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a Bio-Rad gel imager. Unfortunately, the resin did not exhibit any increase in 
fluorescence compared to a negative control, indicating that further optimization 
of the is reaction is necessary. 
Thus far, we have successfully translated the multivalent reaction 
devised by Sun and colleagues to biological conditions. In the future, this 
methodology will be optimized for GFP immobilized on a sepharose bead, as 
well as more relevant enzymes such as SSO Carboxylesterase P1. The 
multivalent enzyme complex can then be assayed for catabolic activity to 
ensure the conjugation did not affect the function of the enzymes. In the future, 
this technology could be applied to create a molecular assembly line, enhanced 
tools for drug delivery or alternative vaccines.  
Materials and Methods 
General: Solvents and reagents were obtained from either Sigma-Aldrich or 
Fisher Scientific and used without further purification, unless noted. Reactions 
were conducted under ambient atmosphere with non-distilled solvents. 
Unnatural amino acids were prepared according to literature protocols.4,5? NMR 
data was acquired on an Agilent 400 MHz. All GFP proteins were purified 
according to manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. 
Mass data was acquired on a Finnigan LCQ Linear Ion Trap mass 
spectrometer. UV irradiation was performed on a Bio-Rad gel imager (Bio-Rad 
Molecular Imager Gel Doc XR+) on the SPYRO Ruby setting. 
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Synthesis of 1: Phenylacetylene (0.93 g/mol, 2.15 mL) was added to THF (24 
mL) in a flame dried round-bottom flask. Copper iodide (CuI, 160 mg) was 
dissolved in TMEDA (0.775 g/mol, 240 μL) and THF (8 mL). This mixture was 
then combined with the Phenylacetylene and stirred overnight (16 h) at 60 ˚C. 
The reaction was then analyzed by Thin Layer Chromatograpgy (TLC) in 
Hexanes and extracted in DCM and brine. The reaction was further analyzed 
by 1H NMR after evaporation on a vacuum line for 2 h (Scheme 2).  
Synthesis of 2: Propargyl alcohol (0.949 g/mol, 2.11 mL) was added to THF 
(24 mL) in a flame dried round-bottom flask. CuI (160 mg) was dissolved in 
TMEDA (0.775 g/mol, 240 μL) and THF (8 mL). This mixture was then 
combined with the Propargyl alcohol and stirred for 48 h while bubbling air 
through at 60 ˚C. The reaction was then purified via column chromatography 
starting with a mixture of 1:3 Hexanes: Ethyl Acetate and ending with a 1:1 
mixture of Hexanes: Ethyl Acetate. The reaction was further analyzed by 1H 
NMR after evaporation on a vacuum line for 2 h (Scheme 2).  
 
Scheme 5.2: Synthesis of the starting materials 1 and 2 via a Glaser-Hay reaction. 
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Multivalent Reaction with 1: Diphenylacetylene (20 mg) and CuI (5 mg) were 
added to Pyrrolidine (0.866 g/mol, 240 μL) in a vial. The mixture was stirred at 
80 ˚C for 6 h, then 15 mL of DCM was added to the vial. The reaction was 
filtered and analyzed by thin layer chromatography (TLC) in Hexanes. The 
crude reaction was subjected to column chromatography using 10:1 Petroleum 
Ether: Ethyl Acetate mixture.2 The fractions were analyzed by TLC and 1H NMR 
in Chloroform after evaporating on a vacuum line for 1 h. This reaction was also 
done at 37 ˚C for 24 h. 
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Multivalent Reaction with 2: Dipropargyl alcohol (20 mg) and CuI (5 mg) was 
added to pyrrolidine (0.866 g/mol, 112 μL) and 10% DMSO in distilled water 
(128 μL) in a vial.2 The mixture was stirred for 26 h at room temperature then 
subjected to column chromatography using 10% Methanol in DCM. The 
fractions were allowed to evaporate for 16 h then analyzed by TLC in 10% 
Methanol in DCM. Fractions 12-15 were sepaated and allowed to evaporate on 
a vacuum line for 3 h, then analyzed by 1H NMR. The presence of aromatic 
Figure 5.5: 1H NMR of 3, from the 80 ˚C multivalent reaction using 
1. All peaks agree with the literature, except the CDCl3 peak at 7.26 
ppm, the water peak at 1.55 ppm, the small peak at 0.08 ppm, and 
the TMS peak at 0 ppm.1 
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peaks prompted further analysis by LCMS, where the product was observed at 
253 m/z.  
 
Incorporation of pPrF: A pET-GFP-TAG-151 plasmid (0.5 µL) was 
cotransformed with a pEVOL-pCNF plasmid (0.5 µL) into Escherichia coli 
BL21(DE3) cells using an Eppendorf eporator electorporator. The cells were 
then plated and grown on LB agar in the presence of chloramphenicol (0.034 
mg/mL) and ampicillin (0.050 mg/mL) at 37 ̊ C overnight. One colony was then 
used to inoculate LB media (4 mL) containing both ampicillin and 
chloramphenicol. The culture was incubated at 37  ̊C overnight and used to 
inoculate an expression culture (10 mL LB media, 0.050 mg/mL Amp, 0.034 
Figure 5.6: Mass Spectra of 4, showing a peak at 253.93 m/z, the 
weight of 4 (252.18 Da) plus one hydrogen within the error of the 
instrument. 
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mg/mL Chlor) at an OD600 0.1. The cultures were incubated at 37 ̊ C to an OD600 
between 0.6 and 0.8 at 600 nm, pelleted and resuspended in 2 mL of media 
containing ampicillin and chloramphenicol. Protein expression was induced by 
addition of pPrF (100 mM, 20 μL) and 20 % arabinose (2 µL) and 0.8 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG; 2 µL). The cultures were allowed 
to shake at 30 ̊ C for 16-20 h then centrifuged at 5,000 rpm for 10 minutes and 
stored at -80 ̊ C for 20 minutes. The cell pellet was re-suspended using 500 µL 
of Bugbuster (Novagen) containing lysozyme, and incubated at 37 ̊ C for 20 
minutes. The solution was transferred to an Eppendorf tube and centrifuged at 
15,000 rpm for 10 minutes, then the supernatant was poured into an 
equilibrated His- pur Ni-NTA spin (Qiagen) column with nickel resin (200 µL) 
and GFP was purified according to manufacturer’s protocol. Purified GFP was 
analyzed by UV irradiation.  
Immobilization of Alkyne onto Epoxy Sepharose 6B Resin Epoxy-activated 
6B Sepharose (GE Healthcare, 200 mg) was added to a filter syringe and 
washed with distilled water (5 x 3 mL). Propargyl alcohol (700 µmol) and 
coupling buffer (3.5 mL, PBS at pH 13.0) was added to a 15 mL tube followed 
by the resin. The mixture was shaken at room temperature for 16 h. The resin 
was transferred to a filter syringe and washed with coupling buffer (4 mL). The 
resin was transferred to a 15 mL tube and capped with ethanolamine (3.5 mL). 
The resin was incubated at 30 ̊C for 4 h then washed (3 x 3 mL) in a filter syringe 
with alternating acetate buffer (10 mM, pH 4) and tris-HCl buffer (pH 8). 
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Glaser-Hay to Alkyne Resin: To an Eppendorf tube, CuI (500mM, 5 μL) was 
added along with TMEDA (500mM, 5 μL). The mixture was equilibrated by 
shaking for 10 min at 37 ˚C. Propargyl Sepharose resin (20 mg) was added, 
and the mixture was equilibrated for 10 min at 37 ˚C. PBS (pH 7.8, 10 μL) and 
GFP-151-pPrF (2.3 mg/mL, 20 μL) were added. The reaction was incubated at 
4 ˚C for 6 h, then washed with PBS (4 x 200 μL). The reaction was analyzed 
via UV irradiation.  
Multivalent Conjugation to GFP Immobilized Resin: Sepharose resin with 
GFP-151-pPrf (20 mg) immobilized was added to a mixture of CuI (1 M, 5.5 μL), 
5-Aminofluorescein (50 mM, 5 μL), and distilled water (45 μL). The negative 
control contained sepharose resin with the propargyl linker immobilized (20 
mg), 5-Aminofluorescein (50 mM, 5 μL), and distilled water (45 μL). Both 
mixtures were incubated with shaking for 6 h at 37 ˚ C while protected from light. 
The resin was then transferred to a spin column and washed with PBS (20 x 
100 μL). The resins were compared to each other by UV-irradiation on a Bio-
Rad gel imager.  
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Chapter 6: Utilization of alkyne bioconjugations 
to modulate protein function 
Protein engineering is a powerful tool for the development of new 
therapeutics, catalysts, and biosensors.1–8 While many advances in the field 
have been made, designing novel protein functionality is still a challenge, as it 
requires an intricate understanding of the subtle interplay between protein 
structure and function. Current engineering techniques often focus on using 
selections and screens to optimize or enhance existing protein functionality.2 
While this method has proved useful for optimizing existing function, generating 
new function where it does not exist is still a hurdle. 
While UAAs have allowed for the development of unique protein function, 
the evolved proteins are often limited to a single new function, depending on 
the UAA incorporated.2,10 In addition, the functionality is limited to the UAA 
itself, which suffers from constraints, such as the requisite for an aminoacyl 
tRNA synthetase capable of recognizing the UAA, the synthetic accessibility 
of the UAA, and the size of the UAA which may preclude its uptake by a 
biological system.9 A more appealing strategy would allow for the generation 
of a UAA-containing protein ‘‘template” upon which researchers could 
synthetically introduce different chemical moieties that would in turn lead to 
altered protein function depending on the moiety employed. 
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Bioorthogonal chemistry, which employs reactions that proceed to 
completion under physiological conditions (pH 7, 37 ˚C), offers a unique 
mechanism to add new chemical functionality to proteins.11,12 Indeed, a 
variety of reactions have been developed that can add novel chemistry to 
living systems. In particular, the cycloaddition between azides and alkynes 
that is either copper(I) mediated or strain promoted has become a widespread 
technique to introduce unique chemistry to proteins.13–16 More recently, our 
group has developed a bioorthogonal variant of the Glaser-Hay reaction,17,18 
which brings together two terminal alkynes to form a diyne in the presence of 
copper(I) under physiological conditions.19–21 The resulting stable diyne 
linkage has a well-defined linear geometry, and due to the abundance of 
commercially available terminal alkynes, a variety of chemical moieties can 
be reacted onto a protein using this technique. As such, we sought to utilize 
the power of this new chemistry to generate new and different protein function 
dependent upon the alkyne reaction partner and not the UAA alone. 
Specifically, we designed a proof-of-concept experiment to alter the function 
of green fluorescent protein (GFP) via reaction of different terminal alkynes onto 
the GFP chromophore. GFP is a 27 kDa protein isolated from Aequorea victoria 
with photochemical properties arising from an internal chromophore composed 
of Ser65-Tyr66-Gly67.22–24 New chemical properties afforded by UAA 
introduction in place of Tyr66 have already been documented to alter GFP’s 
fluorescence profile.25 All UAAs incorporated were found to blue-shift the 
fluorescence profile of GFP, with more highly conjugated UAAs exhibiting a 
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greater degree of spectral shifting. Based on these results, the ability to 
modulate the conjugation of GFP’s fluorophore using UAA mutagenesis is 
apparent, and represents a convenient means to rationally design new protein 
function.26 However, this mutagenesis approach is limited by the size and 
complexity of the UAA. An alternative approach involves exploiting the chemical 
functionality in pre-existing UAAs to serve as functional handles for 
bioorthogonal reactions, acting as a ‘‘template” for the chemical derivatization 
of new protein function. 
This chemically templated protein function could be achieved via the genetic 
incorporation of p-propargyloxyphenyalanine (pPrF, 1) or p-
ethynylphenylalanine (pEtF, 2) into residue 66 of GFP (Figure 6.1).27 This 
provides a terminal alkynehandle for reaction with different chemical moieties 
via the bioorthogonal Glaser-Hay reaction. The resulting diyne linkage is highly 
conjugated, and a prime candidate to introduce new photochemical properties 
into GFP’s fluorophore 
without the need to evolve a 
new aaRS or express multiple 
versions of the protein 
containing different UAAs. 
Moreover, the pEtF (2) is 
directly conjugated with the 
aromatic ring of the UAA, 
allowing for a comparison of 
OH 
N 
N 
O R 
O 
RHN 
HO 
OH H 2 N 
O 
O 
OH H 2 N 
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Tyr 66 
Gly 67 
Ser 65 
Figure 6.1: Modification of GFP function via UAA mutagenesis. 
(A) GFP b-barrel (green) with the chromophore (red) and 
chromophore structure. (B) Unnatural amino acids employed 
as bioconjugation handles. 
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the conjugation between the different UAAs. We hypothesized that the altered 
conjugation and chemical properties around the fluorophore would lead to new 
photophysical properties, demonstrating the utility of a chemically 
programmable protein engineering strategy. Herein we report our findings on 
utilizing the Glaser-Hay reaction on GFP’s fluorophore to alter its fluorescent 
properties. 
In order to obtain protein possessing an alkynyl moiety, a GFP plasmid 
harboring a TAG mutation at position 66 was co-transformed with the 
polyspecific pCNF-aaRS/tRNA pair.28 Conveniently, this aaRS is capable of 
recognizing both 1 and 2 
for expression of an 
alkyne-containing GFP.20 
As the alkynyl UAA is 
incorporated into position 
66 in GFP’s fluorophore, 
the extended conjugation 
afforded by the UAA 
alters the spectral 
properties of GFP. To 
assess that pPrF-
GFPTAG66 was 
successfully produced, 
spectra for the GFP-
Figure 6.3: GFP expression with different alkynyl unnatural amino 
acids. E. coli transformed with a pEVOL-pCNF aaRS plasmid and a 
pET-GFP-66TAG plasmid were induced in the presence of one of the 
alkynyl amino acids. Following Ni-NTA purification, GFP was present 
in all 4 expressions. Small amounts of WT GFP are observed in the 
absence of UAA as previously documented with the promiscuous 
pCNF-aaRS. 
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Figure 6.2:  Fluorescence spectra for the alkynyl containing GFP 
mutants. 
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variant were compared to the wild type (Figure 6.2). These spectra exhibited 
blue-shifts, in agreement with the literature precedent, in the pPrF variant 
relative to the wild type. Incorporation was also confirmed by SDS-PAGE 
analysis of protein expression in the presence and absence of the UAA (Figure 
6.3).  A similar expression was performed using the pCNF aaRS/tRNA pair and 
pEtF to produce a separate GFP mutant with a bioconjugation handle. 
Conveniently, due to the modularity of this approach, only a single protein 
expression is necessary and all functional modification can be achieved 
synthetically. This is in contrast to previous experiments, which required an 
individual protein expression for each UAA in order to modify protein function.  
With a pPrF-GFPTAG66 and pEtF-
GFPTAG66 in hand, we then sought to 
employ our previously reported 
bioorthogonal Glaser-Hay reaction 
to install new and varied chemical 
functionality into the chromophore of 
GFP (Figure 6.4). To investigate, we 
performed bioorthogonal Glaser-
Hay reactions on the chromophore’s 
alkyne handle to couple terminal 
alkyne-bearing aliphatic and 
aromatic compounds with different chemical functionalities. Glaser-Hay 
reactions were performed by using a working concentration of 500 mM of CuI 
Figure 6.4:  Structures of the fluorophores generated 
when performing a Glaser-Hay reaction with the two 
UAAs. (A) Product from the coupling of a terminal 
alkyne to a GFP mutant containing 1. (B) Product 
from the coupling of a terminal alkyne to a GFP 
mutant containing 2. 
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and TMEDA in the 
presence of alkyne-
UAA bearing 
GFPTAG66 and the 
cognate alkynyl 
partner (Scheme 
6.1). Reactions 
proceeded for 4 h at 4 
˚C and then were 
purified via 
centrifugation with a molecular weight cut-off column. The protein was placed 
in phosphate-buffered saline solution (pH 7.2) for analysis using fluorescence 
spectroscopy. Gratifyingly, our initial attempts to couple the terminal alkynes to 
the fluorophore were successful. Furthermore, the different characteristics of 
the installed alkyne moieties successfully shifted the fluorescence profile away 
from the parental alkynyl-GFPTAG66 spectra, each in a unique way. Control 
reactions in the presence of the alkyne but the absence of either the 
CuI/TMEDA or the soluble alkyne afforded no spectral shifts, confirming that 
the protein modification is indeed due to the coupling reaction. While it might be 
expected that the requisite for the reaction to occur within the β-barrel of GFP 
may hinder this reaction from occurring, we hypothesize that the hydrophobic 
nature of the interior of GFP actually aided in the hydrophobic alkyne 
localization, thereby facilitating the reaction by increasing the effective 
concentration. Additionally, SDS-PAGE analysis with Coomassie revealed that 
Scheme 6.1: Glaser-Hay bioconjugations to modify the GFP fluorophore. 
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the Glaser-Hay reaction only minimally altered protein concentration suggesting 
only minimal protein degradation (see materials and methods section).  
We found that our initial Glaser-Hay reactions on pPrF-GFPTAG66 had 
different effects on the fluorescent profile of GFP (Figure 6.5A). Reacting 1-
hexyne (3) on the chromophore caused a general broadening and quasi-red 
shift of the fluorescent spectra. Reacting propargyl amine (4) on the 
chromophore 
caused a 
slight band 
broadening, 
as well as 
potential 
increase in 
fluorescence 
intensity, 
perhaps due 
to the 
increased 
polarity of the 
introduced 
amine group. 
Interestingly, 
coupling with an aromatic alkyne resulted in a dramatic red-shift of the 
Figure 6.5. Fluorescent profile obtained after reacting various alkyne containing partners 
with pPrf or pEtF-containing GFPTAG66. (A) Fluorescent spectra for Glaser-Hay modified 
pPrF-GFP chromophore. (B) Fluorescent spectra for Glaser-Hay modified pEtF-GFP 
chromophore 
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fluorescence to above that of wild-type GFP. Both ethynylanisole (5) and 
ethynylaniline (6), resulted in excitation spectra maxima above 540 nm, 
dramatically altering the fluorescence of GFP. 
We next sought to explore the effects of reacting terminal alkynes in direct 
conjugation with the aromatic ring of residue 66. This was feasible with the GFP 
mutant harboring 2. Interestingly, this strategy resulted in an even greater blue 
shift of the pEtF-GFPTAG66 compared to both the pPrF and wild-type variants, 
likely due to the increased conjugation of the direct attachment of that terminal 
alkyne on the phenyl ring. As a result of this shift, a different excitation 
wavelength was necessary, as 395 nm was found to no longer excite the pEtF-
containing chromophore. Based on absorption experiments, we selected 280 
nm as the wavelength to excite the pEtF-GFPTAG66 and all its Glaser-Hay 
derivatives. In the same fashion as the pPrF, the bioorthogonal Glaser-Hay was 
performed on pEtF-GFPTAG66 using the same reaction partners. Once again, 3 
was found to broaden the fluorescence spectra. Interestingly, 4 had a drastic 
red-shift relative to the pEtF parent chromophore. We believe this helps validate 
our initial speculation that the polarity of the amine has a drastic impact on the 
fluorescent properties of the chromophore, as in this instance the whole system 
is in direct conjugation. Interestingly, when employing the aromatic alkynes in 
the fluorophore modulation, a less dramatic effect was observed than with the 
pPrF mutants. Reaction with 5 only slightly red-shifted the spectra; however, 6 
had a more significant impact both on the intensity and the redshifting of the 
fluorophore. Additionally, attempts to repeat the experiments using the bromo-
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alkyne derivative of 2 under Cadiot-Chodkiewicz coupling conditions resulted in 
the identical spectra, but were performed under more mild reaction conditions 
(Figure 6.6).  These results were expected as the final products of both the 
Glaser-Hay or Cadiot-Chodkiewicz reactions are identical.20 This represents a 
viable alternative reaction to these protein modification approaches. 
Figure 6.6: Comparison of Glaser Hay couplings and Cadiot-Chodkiewicz couplings with anisole (A) and hexyne 
(B) resulting in similar spectral shifts due to the synthesis of identical products. 
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In conclusion, we have extended our work on the biological Glaser-Hay to 
utilize the bioorthogonal chemistry to modulate protein function. Using two 
previously reported alkyne-containing UAAs within the chromophore of GFP 
(position 66), we have successfully performed the Glaser-Hay reaction on the 
chromophore of GFP. The resulting diyne linkage alters the fluorescence profile of 
GFP depending on the moiety attached to the terminal alkyne. Our future work 
seeks to extend the reaction to additional aromatic containing alkynes, which we 
hope will have a greater impact on GFP fluorescence due to the increased 
conjugation found in aromatic systems. Our findings highlight the potential of 
bioorthogonal chemistry, particularly diyne-forming chemistries, to modulate 
protein function without the need for tedious selections and screens. 
Materials and Methods 
General: Solvents and reagents were obtained from either Sigma-Aldrich or Fisher 
Scientific and used without further purification, unless noted. Reactions were 
conducted under ambient atmosphere with non-distilled solvents. Unnatural amino 
acids were prepared according to literature protocols.20 NMR data was acquired 
on an Agilent 400 MHz. All GFP proteins were purified according to manufacturer’s 
protocols using a Qiagen Ni-NTA Quik Spin Kit. Fluorescence data was measured 
using a PerkinElmer LS 55 Luminescence Spectrometer. 
General Biological Glaser-Hay Protocol: To 1.5 mL Eppendorf tube was added 
3 L of a 500 mM CuI solution in water and 3 L 500 mM TMEDA solution in water. 
This mixture was then incubated at 4 oC for 10 mins. Following the incubation, 
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1xPBS (22 L) was added, followed by the alkyne containing GFPTAG66 (10 L) in 
PBS (~0.5mg/mL) and a 40 mM solution (4 L) of the cognate alkyne in DMSO. 
The mixture was allowed to react at 4C for 4 hr.  
Protocol for Fluorimetry Scans: After reacting for 4 hr, 10 L of the reaction 
mixture was added to a quartz cuvette and diluted up to 3 mL with PBS. This was 
then excited at either 395 nm (for the pPrF-containing chromophore) or 280 nm 
(for the pEtF-containing chromophore) with a 10 nm slit width for the excitation and 
emission wavelengths. Slit widths were increased or decreased as necessary 
depending on the intensity of the reaction product’s signal. The scan speed was 
set at 500 nm/min.  
General Protocol for Biological Glaser-Hay with Aromatic Reaction Partners: 
To 1.5 mL Eppendorf tube was added 3 L of a 500 mM CuI solution in water and 
3 L 500 mM TMEDA solution in water. This mixture was then incubated at 4 oC 
for 10 mins. Following the incubation, 1xPBS (22 L) was added, followed by the 
alkyne containing GFPTAG66 (10 L) in PBS (~0.5mg/mL) and a 40 mM solution (4 
L) of the cognate alkyne in DMSO. The mixture was allowed to react at 4C for 4 
hr. Following this, the unreacted aromatic alkyne was washed away using a 10 
MWCO spin column (Corning) and rinsing with 50 L portions of PBS 8 times The 
solution was then concentrated to ~25 L, as indicated on the spin column. Of this 
cleaned solution, 10 L was placed into a quartz cuvette and diluted to 2 mL with 
PBS for fluorescence analysis.  
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Chapter 7: Utilizing 3-Fluorotyrosine to Probe the 
Radical Pathway of Dehaloperoxidase 
Dehaloperoxidase (DHP) is a multifunctional hemoglobin from the terebellid 
polychaete Amphitrite ornata. In addition to the standard globin function of oxygen 
transport, DHP can also preform peroxidase, oxidase and peroxygenase 
functions.1,12 These functions are used by A. ornata to detoxify a wide range of 
chemicals released by nearby organisms, making DHP an exciting target for use 
as a bioremediation enzyme. Additionally, the ability to carry out these four 
functions presents a unique biochemical situation to researchers. Not only is this 
an unusual number of abilities for a single protein, but two functions, globin and 
peroxidase, have very different functional requirements.  The globin function 
utilizes ferrous iron (Fe2+), while peroxidase mechanism relies on ferric (Fe3+) and 
ferryl (Fe4+) iron.1 The exact mechanisms responsible for the transitions between 
these redox states and conflicting functions are still unclear, but are attributed to 
interactions with product radicals and reactant molecules as well as the generation 
of protein tyrosyl radicals. 2,3 
  The position of these tyrosyl radicals have been studied by Dumarieh and 
colleagues by comparing computational Electron Paramagnetic Resonance (EPR) 
spectra simulations and experimentally generated spectra.2 Further non-
computational experiments are needed to confirm these findings, as the nature of 
computational chemistry leaves room for inaccuracies. One such experimental 
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approach is to utilize the unnatural amino acid 3-fluorotyrosine (3-FY). Unnatural 
amino acids (UAAs) can be incorporated site specifically into proteins and 
subsequently used as probes or to confer a novel chemical ability.4 3-FY and 
similar halogenated phenols have been successfully used to probe the structure-
function relationships in myoglobin and bacterial hemoglobin.5,6 In the case of 
DHP, the 3-FY will be used to probe structure-function relationships between the 
tyrosyl radicals and the environment of the protein. 3-FY will create a unique EPR 
spectrum from the natural tyrosine, providing the ability to distinguish between a 
tyrosyl and fluorotyrosyl radical. Characterizing these tyrosyl radicals will allow for 
further exploitation of the DHP’s versatility, whether as a bioremediation catalyst 
or as a model system for the study of peroxidase and other detoxifying functions. 
Discovery and Characterization of DHP 
A. ornata lives near several polychaetes and hemichordates that produce 
toxic halogenated compounds in order to repel predators. A. ornata deals with 
these compounds using 
the A and B isozymes of 
a dehalogenating 
enzyme dubbed 
Dehaloperoxidase 
(Figure 7.1).2 This protein 
oxidizes toxic 
trihalophenols (TXP) to Figure 7.1: Isozymes DHP A and DHP B.2 
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less toxic dihaloquinones (DXQ) 
using a peroxidase mechanism 
(Figure 7.2).7 DHP makes up 3 % of 
the soluble protein in A. ornata, 
indicating its importance as both a globin and detoxifying compound.8 DHP was 
discovered in 1996 when the Woodin lab examined A. ornata’s proteome to find 
the protein responsible for the worm’s immunity to bromophenols.9 DHP exhibited 
a high activity in this study.9  Dawson et. al. found the genes responsible for 
producing the two isozymes in 2004.9 DHP A contains five more amino acids than 
DHP B, including a Y34 residue.2,9 The two isozymes of DHP employ tyrosyl radical 
formation as a part of the peroxidase mechanism. The radicals form first on either 
the Y38 or Y34. If the radical forms on Y38, it will eventually transfer to the Y28.2 
The two isozymes exhibit the same radical formation at Y28 and Y38, but only the 
slightly larger isozyme DHP A possesses a Y34 residue, and thus is the only one 
that can form the Y34 radical.2  
The protein’s overall structure is very similar to other globins. In fact, when 
a sperm whale myoglobin structure is superimposed upon it, the alpha carbons are 
only an average of 1.8 Å apart. This distance means that these two proteins are 
as similar as distantly related globins, indicating that DHP most likely evolved from 
a globin.10 The protein crystallizes as a dimer but is present in solution as a 
monomer, which originally caused some confusion as to whether or not it was the 
coelomic hemoglobin of the worm.8,9 Others have found that DHP has many 
Figure 7.2: Oxidation Reaction via DHP Peroxidase 
Mechanism.7 
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characteristics that are halfway between those typical of globins and peroxidases, 
such as Fe-His55 distance, imidizolate character, and catalytic speed for the 
peroxidase mechanism (for which it is faster than Myoglobin (Mb), but slower than 
Horse Radish Peroxidase (HRP)).3,8,11 Woodin also found that DHP has the ability 
to dehalogenate a wide range of compounds, which is supported by recent studies 
on the peroxygenase and oxidase functions of the enzyme.9,12  
Mechanisms Involved in DHP Function 
 DHP is capable of carrying out four functions: globin, peroxidase, oxidase 
and peroxygenase. This unusual versatility raises several mechanistic questions, 
such as how the protein switches between the globin and peroxidase functions. It 
is known that both the substrate, 
trihalophenol (TXP), and H2O2 must 
be present to facilitate the functional 
switching between the two functions, 
but there is disagreement about the 
exact mechanism. The Ghiladi Lab 
hypothesizes that the binding of TXP 
in the presence of H2O2 is responsible 
for the initiation of the catalytic cycle 
(Figure 7.3). They base this theory on 
precedent in Kat G, HRP and other 
peroxidases, as well as a lack of any 
Figure 7.3: Substrate Binding Mechanism of Activation.7 
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TXP radical species in multiple 
spectroscopic studies.7 Meanwhile, 
the Dawson Lab proposes that trace 
amounts of ferric protein oxidize TXP 
to the TXP radical. This TXP· then 
converts the majority of the DHP from 
oxyferrous (Fe2+) to the ferric (Fe3+) 
form (Figure 7.4). Only once all of the 
protein has been converted to the ferric form does the catalytic cycle start, which 
accounts for the observed lag time between TXP addition and the initiation of the 
catalytic cycle.3 
Another question raised by this unusual protein concerns the protein’s 
ability to circumvent the classical Poulos and Kraut peroxidase mechanism in order 
to begin and end in the oxyferrous state.1 The Poulos and Kraut pathway is 
modeled on Cytochrome C Peroxidase. First the RO2H binds to the resting state 
(7.5a).13 Then an intermediate is formed (7.5b) and next an activated transition 
state. This transition state contains a negatively charged oxygen 1, which is 
stabilized by the positive Arg48. The transition state then undergoes a heterolytic 
cleavage to form the leaving group ROH. This leaves behind a single oxygen 
attached to the Fe3+ (7.5d), which is in resonance with the Fe4+ protein (7.5e). 
These two states are referred to as Compound I. Next, the negatively charged 
oxygen atom abstracts a hydrogen from the nearby Trp51, forming a protein radical 
Figure 7.4: Substrate Radical Activation.3 
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(7.5). Finally, two one-electron oxidations return the protein to its original Fe3+ 
state.13 In most peroxidases, the ferric (Fe3+) and ferryl (Fe4+) states are essential, 
but the oxyferrous (Fe2+) state is catalytically inactive. This presents a problem for 
DHP, whose primary function is to shuttle oxygen in the oxyferrous state.1,14   
 To solve this problem, DHP has evolved the ability to oxidize substrates 
starting from the oxyferrous state, as well as participate in a reaction with DXQ to 
return to the oxyferrous state upon completion of the catalytic cycle (Figure 7.6). 
After initiation of the catalytic cycle, TXP and H2O2 bind to DHP.  H2O2 binds to the 
heme in the distal pocket causing the flexible, distal His55 to swing inward and 
form a hydrogen bond with the H2O2. In high concentrations, TXP will be present 
in the internal binding site above the α-edge of the heme, and at lower 
concentrations, it will bind to the suggested external site above the β- or δ-edge of 
Figure 7.5: Poulos and Kraut Peroxidase Reaction Pathway.13 
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the heme.8 The histidine then acts as a donor base to allow for the cleavage of 
H2O2. This results in the formation of water and leaves an oxygen molecule bound 
to the Fe4+, exactly like the Poulos and Kraut mechanism. In DHP this state is 
known as Compound II and is similar to Compound I in the Poulos and Kraut 
mechanism.7,13 This form of the protein can then oxidize the TXP to TXP· and then 
to a dihaloquinone (DXQ), resulting in the ferric form of the enzyme. The ferric 
DHP can then be either converted either back to the oxyferrous form via DXQ or 
to the intermediate Compound I and then to Compound ES via excess H2O2. 
Compound ES contains a tyrosyl radical, similar to the tryptophenyl radical seen 
Figure 7.6: Total Peroxidase Cycle for DHP.7 
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in Figure 6f of the Poulos and Kraut mechanism.7,13 The intermediate Compound 
I contains a porphyrin radical which is then converted to a series of tyrosyl radicals 
in the protein. Compound ES can then revert to the oxyferrous state via a reaction 
with DXQ, or can convert TXP radicals to DXQ to return to Compound II.7 
Further separating DHP from typical peroxidases is its lack of the catalytic 
Arg-Fe-His triad which aids in the heterolytic cleavage of peroxides. It can be made 
up for by the proximal Methionine 86 or the Leu83-His89-Fe triad present in DHP. 
Met86 is near the proximal Histidine 89. Both functional groups polarize the Fe-O 
bond somewhat, although not as strongly as the Asp-His-Fe triad.8 This 
mechanism can be inhibited by monohalogenated phenols, which bind in the distal 
pocket and force the H55 into the solvent exposed configuration, preventing the 
cleavage of H2O2 and the subsequent initiation of the peroxidase mechanism.11 
This dependence indicates the importance of the flexible H55. 
Additional Capabilities of DHP 
In addition to the globin and peroxidase functions, several new catalytic 
abilities and substrates have been identified for DHP, expanding its potential for 
bioremediation. It can oxidize hydroquinone (HQ) to 1,4-benzoquinone (1,4-BQ).14 
HQ acts as a competitive inhibitor, as it is preferentially oxidized over the native 
substrate, TXP. This could also account for the observed lag phase.14 DHP can 
also oxidize toxic hydrogen sulfide (HS) using the highly flexible H55, indicating 
that DHP could be capable of many more detoxifying functions.15  
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Peroxygenase and concurrent oxidase functions have also been observed 
in DHP (Figure 7.7). The difference between peroxidase and peroxygenase 
chemistry is the origin of the oxygen used for oxidation. In the peroxidase function, 
the oxygen comes from 
solvent water, and in the 
peroxygenase function the 
oxygen comes from the 
H2O2.12,16 In the 
peroxygenase reaction, 
monohalindoles are oxidized to oxindolenine. The subsequent oxidase function 
then utilizes O2, to form indigos. The presence of this function indicates that DHP 
can utilize other pathways besides the TXP· or TXP binding to switch from the 
globin to a catalytic function, and other pathways besides reactions with DXQ to 
return to the oxyferrous state.12 These abilities provide the potential for other native 
detoxifying functions in DHP.12 
Identification of Protein Radicals 
The tyrosyl radicals at Y28, Y34 and Y38, were identified by Dumarieh et 
al. using a combination of EPR spectroscopy, site specific natural amino acid 
mutagenesis and computer simulations.2 Initially, the Tyrosyl Radical Spectra 
Simulation Algorithm (TRSSA) was used to identify the Y34 and Y38 radicals 
present in WT DHP A Compound ES. The EPR spectra computed for each radical 
from the algorithm are shown in Figure 7.8. TRSSA was later used to determine 
Figure 7.7: UV-Vis and Reaction of peroxygenase and oxidase 
functions.12 
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that Y28 was the site of the 
third observed, previously 
unidentified radical. 
Experimental support for these 
computational results was 
garnered by systematically 
mutating the tyrosine(s) in 
question to phenylalanines for both isozymes of DHP. The existence of the Y28· 
was supported by the identical EPR spectra of DHP B Y38F and DHP A 
Y34F/Y38F, where residue 28 was the only potential radical position that remained 
in the active site to confer this signal. This EPR spectra also helped to confirm 
time-dependent radical migration from the Y34 to Y28, as it is identical to the 
spectrum observed after some time for DHP B. The Y38· was confirmed using the 
DHP B Y28F mutant, whose EPR spectra was similar to the one observed in WT 
DHP A at pH 5, which had been previously assigned the Y38 radical. The double 
mutant of DHP B did not exhibit any peroxidase activity, further confirming the 
importance of the tyrosyl radicals to the function of DHP.2 
These tyrosyl radical assignments can be further examined through the use 
of an unnatural amino acid (UAA) probe, 3-fluorotyrosine (3-FY), which exhibits an 
EPR signal unique from that of tyrosine due to the +
3
2
 spin of the fluorine.17 This 
UAA can be synthesized or purchased, then incorporated site specifically into the 
protein in the place of a tyrosine. Any radicals that form on 3-FY can be 
Figure 7.8: ERP Spectra for DHP tyrosyl radicals.2 
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distinguished from the natural tyrosyl radicals. This strategy would minimize any 
structure perturbations observed in phenylalanine mutants, and will allow for the 
normal radical pathway of the protein and the observation of the evolved tyrosyl 
radicals. This approach demonstrates the use of UAAs a powerful tool to confirm 
this radical pathway and to study the effect of experimental conditions on the 
radical pathway. 
This peroxidase mechanism involves the formation of several tyrosyl 
radicals, which were determined using simulations and EPR spectroscopy of 
proteins mutated with non-radical forming phenylalanine. Further study of this 
unusual enzyme can be done through the use of UAAs, in particular 3-FY, which 
can be incorporated site specifically into DHP to probe the characteristics of the 
tyrosyl radicals. 3-FY· will yield an EPR signal unique from that of the natural 
tyrosyl radical, making it a powerful tool to use to study the peroxidase mechanism 
of DHP in real time.  
Results and Discussion 
The DHP mutant DNA was generated by QuikChange PCR site directed 
mutagenesis. The amber stop codon was inserted at positions 34 and 38, tyrosine 
residues that are involved in the radical pathway in only DHP A or in both isoforms, 
respectively. Initially, we selected the DHP A Y34TAG mutant for UAA 
incorporation. DHP containing the 3FY UAA was expressed at 10.5 L using 
pEVOL-3FY E3 synthetase. This synthetase was used instead of the pEVOL-3FY 
E11 synthetase because it is more efficient at charging the orthogonal tRNA with 
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3FY.18 The purity of the expressed mutant 
was analyzed by UV-Vis and compared to 
the wild type (Table 7.1). The mutant was 
run on SDS-PAGE alongside previously 
expressed WT DHP A (Figure 7.9) to 
ensure that the mutant protein was full 
length. A mass spectrum of the mutant 
protein was performed to confirm that 
3FY had been incorporated in the place of 
tyrosine. The mutant was 18.5 m/z 
heavier than the wild type at 16,556.0 
m/z, the weight of adding a fluorine and 
subtracting a hydrogen from the wild type 
at 16,537.5 m/z. The mass spectra and 
SDS-PAGE both confirmed that the 
unnatural amino acid had been incorporated at position 34 into a full-length DHP 
A protein.  
The mutant DHP was then assayed for peroxidase activity using established 
protocols and compared to wild type DHP A, DHP B and DHP A containing a 
phenylalanine substituted at the 34 position (Table 7.2).2 The mutant DHP 
exhibited a slightly lower binding affinity (Km) than the phenylalanine mutant and 
the wild type proteins, although the difference is only approximately two-fold. The 
Table 7.1: UV-vis characteristics of DHP A 
Y34Y3F and DHP A WT.2 
Figure 7.9: DHP A Y34Y3F and DHP A WT. 
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same is true to a lesser 
extent for the rate (kcat), 
which is slightly higher in 
the 3FY mutant than the 
other DHP proteins. Due to 
these slightly higher 
values in the mutant, the 
3FY mutant catalytic 
efficiency (kcat/Km) value was lower than the other proteins. While these differences 
are outside of the range of error and statistically significant, they are not large 
enough to indicate that the 3FY mutant is performing the peroxidase function using 
a different mechanism than the other DHP proteins. This means that we can 
continue to stopped-flow studies on the peroxidase mechanism and eventually 
onto EPR studies to study the iron intermediates and radicals that arise during the 
peroxidase reaction in our mutant. 
The DHP A Y34TAG single mutant was also induced at 10 mL 2,3-FY, 3,5-
FY, 2,3,5-FY and 2,3,6-FY, then the protein was subjected to SDS-PAGE (Figure 
7.10). Incorporation of these other fluorotyrosines would allow us to probe the 
radical mechanism more thoroughly, as each would give a unique EPR spectra. 
Two different fluorotyrosines could be incorporated into DHP A using another 
synthetase system, allowing for the simultaneous monitoring of all three tyrosine 
Table 7.2: Kinetic Values for DHP A Y34Y3F, DHP A Y34F, DHP A, 
and DHP B.2 
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residues involved in the 
radical pathway.19 Only 
the 2,3,6-FY yielded 
any appreciable amount 
of protein, which is 
surprising considering 
that the pEVOL-3FY E3 
is better at charging the 
other fluorotyrosines to 
the orthogonal tRNA.18 
In the future, this DHP A 
Y34Y2,3,6FY protein will be re-expressed on a larger scale. This mutant will also be 
analyzed by UV-vis spectroscopy to analyze its purity and subjected to the 
peroxidase assay to determine what affect the triply substituted tyrosine has on 
the radical mechanism. Given the low yield of the previous experiment the terminal 
amber stop codon was replaced with the opal stop codon, TGA, to yield the DHP 
A Y34TAG double mutant. This was done to prevent insertion of the unnatural at 
two positions and to make the synthesis of DHP more compatible with E. coli, as 
TGA is used more frequently in E. coli than TAG.20 
Transition of the experiments to the Young lab encountered some difficulty, as 
even expression of the WT protein became problematic. Thus, the expression of 
DHP A WT was used to troubleshoot the small-scale expression. Expressions 
Figure 7.10: DHP A 34 expressed with 2,3,5-FY and 2,3,6-FY compared 
to DHP A WT. 
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done by concentrating the induction mixture, inducing the cultures at the end of the 
log phase (OD600 0.9), and expression of the DHP A 34 single mutant with another 
UAA, p-propargyloxyphenylalanine (pPrF), were attempted without any 
appreciable protein yield. Scaling up the expressions to 200 and 250 mL yielded a 
red solution with a soret at 416 nm indicating the presence of DHP A WT in the 
oxyferrous form. However, no protein at the appropriate molecular weight was 
visible via SDS-PAGE. This, combined with the low intensity of the soret lead to 
the conclusion that DHP A WT had been expressed at a very low concentration. 
This protein will be assayed for peroxidase activity to confirm that functional DHP 
was expressed, then this method will be applied to express DHP A Y34Y2,3,6FY for 
further analysis.  
DHP A Y34TAG has proven challenging to express in good yield, but 
nevertheless it is possible to express this protein with an unnatural amino acid, in 
particular 3-fluorotyrosine and 2,3,6-fluorotyrosine. In the future, this expression 
method will be optimized and extended to the DHP A Y38TAG mutant to further 
investigate the radical mechanism of DHP. The kinetic values and intermediates 
of the DHP A 34 and 38 mutant proteins will be analyzed using UV-vis, stopped-
flow UV-vis and rapid freeze quench EPR spectroscopy. This investigation will 
result in an enhanced understanding of the mechanism of this unique 
multifunctional hemoglobin and offer insights into the mechanisms of other 
hemoglobins.  
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Materials and Methods 
General: All PCR was performed on a Biorad icycler, with the QuikChange II Kit. 
Mass spectra were acquired on a Thermo Fisher Scientific Exactive Plus MS 
orbitrap using a liquid chromatography-heated electrospray ionization source. The 
mass spectrum was acquired at the NCSU Mass Spectrometry Facility located in 
the Department of Chemistry. All reagents were obtained from Acros, USB, 
Biotium, Alfa Aesar or Amresco and used without further purification unless noted. 
All absorbance data was acquired on a Thermo Scientific Nanodrop 2000. 
Quik-Change PCR Protocol: The plasmid harboring DHP A was diluted to 24.7 
ng/µL, 12.3 ng/μL, and 6.2 ng/μL. The PCR reaction mixture contained 1 μL of one 
of the dilutions of the plasmids, 1 μL 10 mM DNTPs, 1 μL of Pfu Polymerase, 1 μL 
of forward primer (10 μM), 1 μL of reverse primer (10 μM), 5 μL Pfu Buffer, and 
40μL of ultrapure water. The reaction mixture was subjected to the following 
heating protocol: 95 ˚C (1 min); eighteen cycles of melting (95 ˚C, 30 s), annealing 
(55 ˚C, 30 s), and extension (68 ˚C, 6 min); a final extension period (68 ˚C, 6 min) 
and then held at 4 ˚C. Next the parent plasmid was digested by adding 2 μL of 
DPN1 [20,000 units/μL] and subjecting the mixtures to the following heating 
protocol: 37 ˚C 2 h and heat deactivation (80 ˚C, 15 min). The reaction was 
transformed (2 μL) into BL21 DE3 E. coli cells by heat shock. The transformed 
cells were plated (250 μL) onto agar containing ampicillin and incubated at 37 ˚C 
overnight. The resulting cells were inoculated and grown in liquid culture overnight, 
then miniprepped using IBI High Speed Plasmid Mini Kit. The resulting plasmids 
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were analyzed for successful insertion of the TAG mutation by sequencing at 
Genewiz. The primers were obtained from IDT DNA Technologies Inc. Y38TAG 
5’-GTC AGA TTT GCC GAC CTA GTT TTT GAA GTA GCG-3’ (forward), 5’-CGC 
TAC TTC AAA AAC TAG GTC GGC AAA TCT GAC- 3’ (reverse), Y34TAG 5’-CGA 
CAT AGT TTT TGA ACT AGC GGC GCT CGT-3’ (forward), 5’-GAC GAG CGC 
CGC TAG TTC AAA AAC TAT GTC G-3’ (reverse). 
Expression and Purification of Protein: The plasmid harboring a variable DHP 
TAG mutant (0.5 μL) was co-transformed with a pEVOL-3FY E11 plasmid (0.5 μL) 
into BL21 (DE3) cells using an Eppendorf eporator electorporator. The cells were 
then plated and grown on LB agar in the presence of chloramphenicol (0.034 
mg/mL), ampicillin (0.050 mg/mL) at 37  ̊C overnight. Two colonies were then used 
to inoculate two separate aliquots of LB media (5 mL) containing ampicillin and 
chloramphenicol. The cultures were incubated at 37 ̊ C overnight and used to 
inoculate an expression culture (1.5 L LB media, 1.5 mL 50 mg/mL Amp, 1.5 mL 
34 mg/mL Chlor, 10 mL 0.01 mg/mL Hemin) at an OD600 0.1. The cultures were 
incubated at 37 ̊ C to an OD600 between 0.6 and 0.8 at 600 nm, and protein 
expression was induced by addition of 3-Fluorotyrosine (15 mL, 100 mM) and 20 
% arabinose (1.5 mL) and 0.8 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; 
1.5 mL). The cultures were allowed to shake at 32  ̊C for 16-20 h then centrifuged 
at 4,150 rpm for 20 minutes and stored at -80  ̊C for 16 h. The cell pellet was re-
suspended in a solution of 100 mM sodium phosphate, 20 mM imidazole. The cells 
were lysed by addition of 1 mg/mL Lysozyme, 10 mg/mL Soybean Trypsin 
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Inhibitor, phenylmethylsulfonyl fluoride (75 mg/mL), Tosyl phenylalanyl 
chloromethyl ketone (10 mg/mL), Triton x-100 (1 mL) and sonication. The mixture 
was centrifuged for 1 h at 12,000 rpm. The supernatant was then centrifuged for 
30 min at 12,000 rpm. The supernatant was then loaded onto an equilibrated nickel 
column for affinity chromatography, where the protein was washed with a pH 8 
solution of 0.1 M sodium phosphate, 20 mM imidazole, 0.5 M NaCl until the flow 
through was clear. The protein was then eluted with a pH 8 solution of 0.1 M 
sodium phosphate and 200 mM imidazole, 0.5 NaCl. Excess potassium 
ferrocyanide was added to the elution to convert all the protein to the ferric form. 
The solution was then concentrated to one-fifth of the original solution and buffer 
exchanged via PD10 column. The resulting protein was then loaded onto an 
equilibrated CM- 52 column.  Minor fractions were collected by washing the column 
with a solution of 10 mM potassium phosphate at pH 7. Major fractions were then 
collected by washing the columns with 38 mM potassium phosphate at pH 7. 
Protein concentrations were determined by UV-Vis measurements at 407 nm. The 
purity and size of the protein was analyzed by UV-Vis,  SDS PAGE (12%) and 
LCMS. 
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Peroxidase Assay: The purified protein was assayed for peroxidase functionality 
to compare kinetic values to the wild type. The protein (0.5 μM) was mixed with 
trichlorophenol (150 μM) and varying concentrations of hydrogen peroxide (50, 
100, 250, 500, 1000, 1250 μM) to a total volume of 250 μL in 100 mM Potassium 
Figure 7.11: UV-vis spectrum of ferric DHP A 34+3FY. 
Figure 7.12: Michaelis-Menten plot of DHP A 34+3FY performing the 
peroxidase reaction. 
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Phosphate Buffer (pH 7). Absorbance readings were taken every 0.6 s at 276 nm 
and 312 nm.  
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